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 1 Introduction 
Tuberculosis (TB) is the leading cause of mortality worldwide caused by any one 
bacterium.  It is an important common contagious disease with public health problem in 
both the developed and developing countries. TB is caused by Mycobacterium 
tuberculosis, a pleomorphic, non-motile, non-spore forming acid-fast bacterium 
belonging to the family Mycobacteriaceae. It has unusually high GC content (65%) in 
its genomic DNA and also a very high lipid content in the cell wall, which accounts for 
more than 50% of dry weight of the cell (Barrera 2007). M. tuberculosis is a slow 
growing intracellular pathogen, requiring approximately 20 hours to replicate. 
TB can be considered as an ancient disease which can be traced back to the ancient 
Egyptian civilization ca. 1550–1080 BC (Nerlich et al. 1997). A recent specimen found 
in Turkey of early evolving human was diagnosed with TB caused by Leptomeningitis 
tuberculosa (Kappelman et al. 2008) thus making the relation of TB with human back to 
500,000 years.  
Due to the improving living standard, health systems and hygienic condition, the 
prevalence of TB decreased in the 20th century. However this phase did not last long. 
Since the late 1980s an alarming  global resurgence of TB has been observed, 
particularly in developing countries (Kochi 1991).  
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Fig. 1. Estimated global and incidence rate of tuberculosis, 1990–2006. Source: (WHO 2008)  
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One third of the human population is infected by TB, of whom 5-10% will develop 
active disease. The organism has the ability to stay in a dormant phase in host allowing 
asymptomatic infection that may persist for decade or life long. However, during the 
weakening immunity as is caused by malnutrition, old age or diseased condition e.g. in 
person infected with HIV (Human immunodeficiency virus), M. tuberculosis is 
reactivated and leads to active TB (Smith 2003). The TB epidemic situation is worsened 
by HIV pandemic with almost 13 million people currently co-infected with HIV and TB 
(Barnes et al. 2002). 
Dormancy has been associated with non-replicating or very slow growth of M. 
tuberculosis that resides in granulomas, a heterogeneous assembly of macrophages, in 
the lungs of infected individuals. It is generally assumed that the microenvironment in 
the granulomas is characterized by hypoxia, nutrient starvation and reactive oxygen and 
nitrogen species (Wang 1991; Fenton and Vermeulen 1996; Zhang 2004). 
 
1.1 Epidemiology of TB 
Between 2-3 million people die from this disease alone and some 8-10 million new 
cases are reported every year (Porter 1991), which accounts for the total infected 
individuals to 1700 million. An estimated 1.7 billion people, i.e. one-third of the 
population, carries the causative agent of the disease and thus risking the development 
of disease whenever the immunity of individual weakens. The report regarding the 
incidence of TB worldwide has increased steadily from 1990 to 2004 from 124 million 
to 141 million cases.  
Most of the deaths from TB is caused by the synergistic relationship of TB with HIV. 
As of 2006, 9.2 million new cases and 1.7 million deaths from TB were reported, of 
which 0.7 million cases and 0.2 million deaths were in HIV- positive people (WHO 
2008).  
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Fig. 2. Notified TB cases (new and relapse) per 100 000 population. Source: (WHO 2008) 
 
 
1.2 Emergence of drug resistant TB 
For TB therapy, 6-9 month of chemotherapy with first line anti-TB drug combinations 
of isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and ethambutol (ETH) are 
prescribed. 
However patients infected with Multiple Drug resistant TB (MDR-TB) require second 
line drugs, which have significantly more side effects to the patients. MDR-TB is 
resistant against two or more first line drugs. Recent trend of MDR-TB is rising which 
has led to an alarming  situation and failurein treating MDR-TB. With the evolution of 
drug resistant organisms, the current chemotherapies are insufficient and novel therapies 
to deal with the rising resistant TB are needed. Until recently, drug development was in 
sluggish phase, due to technical limit, the size of potential market and due to the higher 
rate of the disease in the developing world (Copeland 2005).  
The genetic basis of antibiotic resistance in clinical strains is predominantly attributed 
to mutations in specific genes or their promoter region. Extensive Drug Resistant or 
No report 
0–24 
25–49 
50–99 
100 or more 
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Extreme Drug Resistance (XDR) tuberculosis can be defined as TB that is resistant to 
first- and second-line drugs. In other words it is resistant to both rifampicin and 
isoniazid and in addition resistant to any fluoroquinolones, and to at least one of three 
injectable second-line anti-tuberculosis drugs (capreomycin, kanamycin, and amikacin) 
used in the treatment of tuberculosis. 
Increase in the incidence of XDR-TB has added more problems to the already serious 
TB epidemic.  
 
Fig. 3. Countries with confirmed cases of XDR-TB as of March 2007. 
 
 
Until March 2007, XDR-TB was detected in 24 different countries (Fig.3). By February 
2008 the number increased to 47 countries (WHO 2008). Just within a difference of one 
year, the reported XDR-TB cases increased in 23 countries, which is a clear indication 
of worldwide spread of XDR-TB. 
XDR TB reported in 24 
Countries as of March, 2007 
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Fig. 4. Countries with reported cases of XDR-TB as of Feb 2008 increased up to 24. 
 
1.3 Current therapies 
Currently there are ten antituberculosis drugs approved by the United States Food and 
Drug Administration (FDA). Additionally, the fluoroquinolones, which are not 
approved by the FDA for TB, are also commonly used to treat TB caused by drug 
resistant strains or for patients who are intolerant to some of the first line of drugs.  
The currently available antituberculosis agents and their modes of action are tabulated 
below.  
 
XDR-TB reported in 47 
countries as of Feb, 2008 
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Table 1. Antituberculosis agents, their mode of reaction and the target gene(s) of pathogen. 
Antituberculosis Agent Action of Inhibition Target Gene 
First line drugs 
Rifampicin Bacterial RNA polymerase 
 
rpoB (Telenti et al. 1993) 
Isoniazid Inhibitors of Cell Wall Synthesis. 
Inhibition of mycolic acids synthesis in M. 
tuberculosis (Winder et al. 1970; Winder and 
Collins 1970) 
katG encoded catalase 
peroxidase (Heym and Cole 
1992; Zhang et al. 1992; 
Cockerill et al. 1995; Heym et al. 
1995; Pym et al. 2002) 
 
 
inhA encoded long chain enoyl-
ACP reductase (Quemard et al. 
1995) 
 
ahpC (Wilson and Collins 1996; 
Chen et al. 2005) 
Pyrazinamide Acidification of cytoplasm and de-enerizes 
membrane by hydrolyzing pyrazinamide (Konno 
et al. 1967; Butler and Kilburn 1983) 
 
pncA (Scorpio et al. 1997) 
Ethambutol Inhibition of arabinogalactan synthesis, which is 
necessary for the construction of the outer 
envelope of the mycobacterial cell envelope 
(Sareen and Khuller 1990) 
embA,embB, embC 
(Sreevatsan et al. 1997) 
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1.4 Rifampicin 
Rifampicin (Rif) was first introduced in 1972 as an antitubercular drug which was 
extremely effective against M. tuberculosis. It has since then proved as the most potent 
and the most effective drug against TB. It has minimum inhibitory concentration (MIC) 
of 0.1 µg to 0.2 µg (Woodley et al. 1972). It is a  first-line drug for the treatment of all 
sorts of TB with known or presumed sensitivity to drug. It has an activity against 
organisms that are in log phase (Jindani et al. 1980) or semidormant bacterial 
population, thus accounting for its antibiotic activity (Dickinson and Mitchison 1981). It 
is a semi-synthetic antibiotic derived from rifamycin B which is a fermentation product 
of Streptomyces mediterranei. The structure of Rifampicin is shown in figure 5. 
Second line drugs 
Fluoroquinolones 
(Levofloxacin, 
moxifloxacin, 
gattifloxacin, 
ciprofloxacin, ofloxacin) 
Inhibition of DNA gyrase, an ATP-dependent Type 
II DNA topoisomerase that catalyzes the negative 
supercoiling of DNA (Wang 1991) 
gyr (Wang 1991; Takiff et al. 
1996) 
 
lfrA (Takiff et al. 1996) 
Capreomycin Inhibition of translation by affecting ribosomes rrs (16S RNA) (Taniguchi et 
al. 1997; Suzuki et al. 1998) 
 
 tlyA (Maus et al. 2005) 
Cycloserine Peptidogylcan synthesis alrA, gadA y 
Streptomycin and Related 
Aminoglycosides 
Drug inactivation via acetylation (Benveniste and 
Davies 1973) 
However, this mechanism of resistance has not been 
reported in M. tuberculosis. 
rpsL gene (Finken et al. 1993; 
Nair et al. 1993; Meier et al. 
1994) 
Amikacin and Kanamycin Inhibition of protein synthesis rrs (16S RNA) (Maus et al. 
2005) 
 
Ethionamide Inhibition of mycolic acids synthesis in M. 
tuberculosis  
(Winder et al. 1970; Winder and Collins 1970) 
katG encoded catalase 
peroxidase (Heym and Cole 
1992; Zhang et al. 1992; 
Cockerill et al. 1995; Pym et 
al. 2002) 
 
 
inhA encoded long chain 
enoyl-ACP reductase 
(Quemard et al. 1995) 
 
ahpC (Wilson and Collins 
1996; Chen et al. 2005) 
p-Aminosalicylic Acid Inhibition of iron uptake, Folic acid biosynthesis 
(Rengarajan et al. 2004) 
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Fig. 5. Structure of Rifampicin 
 
The DNA-dependant RNAP is one of the key enzyme in the central dogma of all living 
being. This enzyme synthesizes RNA copy from a DNA template during the process of 
gene transcription. The RNAP structures of Thermus aquatus and E. coli are known. 
Rifampicin has a specific inhibitory action against bacterial RNA polymerase (RNAP) 
and little effect on human RNAP. The molecular basis of action of rifampicin has 
already been well characterized in Escherichia coli (Wehrli 1976; Jin and Gross 1988). 
Rifampicin binds in a pocket of the RNAP β subunit deep within the DNA/RNA 
channel and blocks the RNA exit pathway. As a result, RNAP bound to rifampicin is 
able to initiate RNA chain synthesis, but is unable to elongate the RNA product beyond 
a length of 2–3 nucleotides (Campbell et al. 2005). The vast majority of rifampicin 
resistant mutants harbor substitutions in RNAP β subunit residues that either make 
direct contacts with Rifampicin or are located near the binding pocket (Campbell et al. 
2001). The mechanism of action of rifampicin in Mycobacterium smegmatis, a fast 
growing closely related species of M. tuberculosis has been studied in detail (White et 
al. 1971).  
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1.5 RNA polymerase of  M. tuberculosis and  drug resistance 
The RNA polymerase of M. tuberculosis has been studied extensively since decades. It 
is a multi-subunit structure composed of several subunits like RpoA, RpoB, RpoC, and 
RpoZ and sigma unit. It is a relatively large molecule of about 363 kDa (Cole et al. 
1998). The core enzyme consists of four subunits comprised of α2, β, and β’, which 
catalyse the synthesis of RNA. The promoter-specific transcription initiation requires 
core enzyme together with σ subunit, which together makes up holoenzyme. In M. 
tuberculosis genome 13 putative σ factors are present (Cole et al. 1998) and most of 
those found to be associated with virulence (Smith 2003).  
The α subunit of the RNAP with molecular mass of 37.7 kDa contains 374 amino acid, 
is encoded by rpoA gene, which is 1044 bp long. There are two subunits in RNAP. It 
helps in initiating the assembly of the enzyme and recognizes regulatory factors.  
 The β subunit is encoded by 1172 nt rpoB gene of M. tuberculosis. It is relatively large 
protein with molecular mass of 129 kDa and 1172 amino acids. It is the core unit of 
RNAP. 
The β’ subunit is the largest subunit with molecular mass of 146.7 kDa. It contains 1316 
amino acids and is encoded by rpoC gene. It binds to DNA non-specifically. 
The ω subunit is 11.8 kDa, encoded by rpoZ gene with 333 amino acids. Its function is 
not known in detail but it is assumed to restore denatured RNA polymerase to its 
functional form in vitro. It promotes assembly of RNAP. 
As a result of mutation in the rpoB gene specific  conformational changes result in  
defective binding of the drug (Jin and Gross 1988). At least 66 different kinds of 
mutation are already characterized which are related to the resistance against rifampicin 
(Jin and Gross 1988). Most mutations are restricted to a 69-bp region and are dominated 
by single nucleotide changes resulting in single amino acid substitutions as shown in  
Fig. 6.  
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Fig. 6. Distribution of mutations within the rpoB gene in M. tuberculosis. The arrows and numbers 
indicate the number of codons that were omitted from the diagram as they had no mutation. Source: 
(O'Sullivan et al. 2005) 
 
 
1.6 Pyrazinamide 
Pyrazinamide (PZA), an analog of nicotinamide, is one of the most important drugs for 
anti-TB shortcourse chemotherapy, particularly it is the only drug which is  bactericidal 
to dormant M. tuberculosis (Heifets and Lindholm-Levy 1992) and is effective  in the 
acidic environment inside macrophages where M.tuberculosis primarily resides and 
survives (Dickinson and Mitchison 1970; Mitchison 1985). It is a prodrug for 
tuberculosis, which requires conversion to the bactericidal compound pyrazinoic acid 
(POA) by bacterial pyrazinamidase (PZase) activity (Blanchard 1996). The specific 
action of POA is not yet known, but it has been suggested that accumulation of POA 
results in a pH reduction leading to non-specific inhibitory effect on cellular metabolism 
(Boshoff et al. 2002). It has been shown that POA can disrupt M. tuberculosis 
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membrane potential, affecting the transport function at acidic environment (Zhang et al. 
2003). The report by Ngo (Ngo et al. 2007) that PZA and POA were able to inhibit 
mycobacterial fatty acid synthase I (FASI) has not been confirmed and is controversial.  
 
1.6.1 Pyrazinamidase and drug resistance 
PZase is an amidase, which converts amide to an acid. In M. tuberculosis it is encoded 
by 561 nt pncA gene, which produces 19.6 kDa protein consisting of 186 amino acids.  
 
 
 
Fig. 7. Schematic representation of pyrazinamidase  and nicotinamidase reaction. 
Source: (Frothingham et al. 1996) 
 
Mutations leading to a loss of PZase activity cause PZA resistance in M. tuberculosis 
(Konno et al. 1967; McClatchy et al. 1981; Butler and Kilburn 1983; Trivedi and Desai 
1987; Miller et al. 1995). This is the major mechanism of PZA resistance in clinical 
isolates of M. tuberculosis (Scorpio et al. 1997; Sreevatsan et al. 1997; Lemaitre et al. 
1999; Marttila et al. 1999; Cheng et al. 2000; Miyagi et al. 2004; Jureen et al. 2008; 
Mphahlele et al. 2008). However, all PZA resistant strains of M. tuberculosis do not 
contain mutation in pncA, suggesting presence of alternative mechanisms for PZA 
resistance. Different studies showed that 72-97% of PZA resistant M. tuberculosis 
harboured mutation in pncA gene or in its regulatory region (Sreevatsan et al. 1997; 
   
12 
Rodrigues Vde et al. 2005; Barco et al. 2006; Jureen et al. 2008). The crystal structure 
PZases of P. horikoshii has been solved (Fig. 8).  
 
 
Fig. 8. Crystal structure of nicotinamidase of Pyrococcus horikoshii 999 (PDB ID: 1ILW). α-Helices and 
β strands are colour-coded in cyan and green, respectively. The three loops in red (from residues 10 to 21, 
128 to 133, and 52 to 72, respectively) contribute most to the scaffold of the active site. Mutations that 
confer PZA-resistance show some degree of clustering in the corresponding regions of PZase of M. 
tuberculosis. (Du et al. 2001) 
 
A comparaison of the PZAse of M. tuberculosis, M. smegmatis and E. coli shows that 
the active site of the PZase in M. tuberculosis probably lies in the 8-18, 49-71 and 96-
102 amino acid residues  PZase (Du et al. 2001). 
In M. smegmatis, fast growing mycobacterium  there are two known enzymes (PncA 
and PzaA) responsible for the amidase activity (Guo et al. 2000).  
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1.7 Summary 
In summary, following are the main reasons for the global re-emergence of TB and the 
increasing prevalence of MDR and XDR TB: 
 
1. Inadequate, inacurate  and slow diagnosis of infection and TB disease by 
currently available means by sputum microscopy, culture, chest radiography and 
molecular means. This is also true for the diagnosis of resistant strains. 
 
2. Incomplete protection by M.bovis BCG, the only vaccine used world-wide 
 
3. Longe term treatment duration of TB therapy leading to non-compliance and 
hence emergence of MDR and XDR TB. 
 
4. Inavailability of drugs to treat MDR and XDR TB 
 
There is an urgent need for a better understanding of the mechanisms of resistance to 
antibiotics in M. tuberculosis and for the development of rapid assays suitable for high-
throughput screening for the development of new drugs not only against MDR and 
XDR TB but also for the treatment of persistent and latent tuberculosis infection 
(LTBI). 
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1.8  Objectives of the study 
The objectives of the study were to investigate drug resistance in clinical strains of M. 
tuberculosis and to evaluate currently available assays and/or to develop new assays 
suitable for drug development for resistant MDR and XDR strains. 
 
More specifically, the objectives  were: 
1. Evaluate current assay for RNAP and PncA (PZAse). 
2. Attempt to reconstitute M. tuberculosis RNAP holoenzyme for use in drug 
screening. 
3. Screening of  potential drug candidates using the optimized assay for RNAP. 
4. Identify mutation in pncA gene which are responsible for Pyrazinamide 
resistance. 
 
 
The work presented in this thesis was done independently but forms a part of large 
international research project on TB drug develeopment “PERSISTENT TB” and 
“NEWTBDRUGS”  supported by the European Union (Coordinator: M. Singh, 
Braunschweig, Germany). These projects have focussed on an  integrated strategy of 
drug development by structural analysis of novel targets, virtual and real screening 
based identification of leads, new organic synthetic chemistry and functional evaluation 
of best hits in in-vivo mouse model. Following identification of novel drug targets, 3-D 
structure of several targets (Tpx, NirA, CysK1, CysM, ALADH)  validated by gene 
inactivation has been solved (Schnell et al. 2005; Stehr et al. 2006; Schnell et al. 2007; 
Agren et al. 2008) ;CysH; manuscript in preparation). 
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2 Materials and Methods 
2.1 Chemicals and reagents 
2.1.1 For routine lab work 
Table 2. Chemicals used for routine lab work. 
Chemicals Company Comments 
Acetic Acid Roth SDS Gel Destaining 
Acrylamide Roth SDS 
ADC Enrichment BD Enrichment for Medium 
Adenosine-5´-triphosphate-γ-(4-
methylumbelliferyl) ester 
Hannover University Fluorescent RNAP Assay 
Agar Difco Medium 
Agarose Roth DNA Gel 
Alkaline phosphatase  Fermentas Fluorescent RNAP Assay 
Ampicillin Sigma Aldrich Antibiotics 
AMPSO Fermentas Fluorescent RNAP Assay 
APS Super Broth Otto Nord Wald Protein Expression 
Benchmark Protein Ladder Biotage Protein Standard 
BioMix 500 Bioline PCR Kit 
BSA Standard Set Bio-Rad Protein Estimation 
Buffer Solution pH=9.0 und 7.0 Roth pH Calibration 
Bug Buster Merck Biosciences Cell Disruption 
Coomassie Brillantblue Serva SDS 
Coomassie Plus Prot. Assay 
Reagent 
Pierce Protein Estimation 
Crystal Screen  Hampton Crystallization Trial 
Crystal Screen 2  Hampton Crystallization Trial 
DTT Sigma Aldrich SDS 
Ethambutol Sigma-Aldrich Antibtiotics 
Ethanol J. T. Baker Various uses 
GelStar Nucleic Acid Stain Lonza Verviers DNA Staining 
GeneRuler™ 1 kb Plus DNA 
Ladder 
Fermentas DNA Ladder 
GeneRuler™ 100 bp DNA Ladder  Fermentas DNA Ladder 
GeneRuler™ 1kb DNA Ladder Fermentas DNA Ladder 
Glycerol Roth Various uses 
Guanosine-5´-triphosphate-γ-(4-
methylumbelliferyl 
Hannover University Fluorescent RNAP Assay 
Guardian Peroxidase Conjugate 
Stabilizor Diluent 
Pierce Western Blot 
Hepes Sigma Aldrich Buffer 
Histidine Tag Dianova GmbH Western Blot 
Imidazol Sigma Aldrich Buffer 
Immuno Pure Antibody (Anti 
Goat- Mouse IgG labelled HRP) 
Pierce Western Blot 
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IPTG Roth Inducer 
iso-Propanol J. T. Baker Various uses 
JCSG+ Suite Qiagen Crystallization Trial 
Kanamycin  Sigma Aldrich Antibiotics 
Mercaptoethanol Roth SDS 
Methanol Various Use 
Middlebrook ADC BBL Mycobacterial Medium 
MnCl Sigma Aldrich Buffer 
N,N,N’,N’-
Tetramethylethylenediamin 
Sigma Aldrich SDS 
NAD Roth Enzyme Assay 
NADH Sigma Aldrich Enzyme Assay 
NADP Sigma Aldrich Enzyme Assay 
NADPH Roth Enzyme Assay 
Ni-NTA  Qiagen Protein Purification 
OADC Encrichment BD Enrichment for Medium 
PACT Suite Qiagen Crystallization Trial 
PageRuler™ Prestained Protein 
Ladder 
Fermentas  Protein Standard 
PageRuler™ Protein Ladder Fermentas  Protein Standard 
Peroxidase Conjugate-Goat Anti-
Mouse IGM 
Sigma-Aldrich Western Blot 
Poly(ethylene glycol) Sigma-Fluka Various Use 
Polyoxyethylene Sorbitan Omon 
oelate (Tween 80) 
Sigma Aldrich Medium 
Potassium Chloride Fluka Various Use 
Potassium dihydrogenphosphate Merck Various Use 
Potassium Iodide Serva Buffer 
Potassium Sulphate Roth Buffer 
Q Sepharose GE Health care Protein Purification 
QIAquick Gel Extraction Kit Qiagen PCR Extraction 
RNaseA Qiagen Buffer for MiniPrep 
SDS ultra Roth SDS 
Sephadex GE Health care Protein Purification 
Sodium Chloride Roth Various Uses 
Sodium dihydrogen Phosphate Sigma Aldrich Various Uses 
Sodium Hydroxide Roth Various Uses 
TaKaRa LA Taq + Mg plus buffer Mobitech PCR Kit 
Taq DNA Polymerase Qiagen PCR Kit 
TMB/Substrate Solution Seramum, Diagnostic GmbH Western Blot 
Tris-Base Sigma Aldrich Buffer 
Tris-HCl Sigma Aldrich Buffer 
Trypton BD Medium 
Urea J. T. Baker Protein Denaturation 
Yeast Extract BD Medium 
Zinc Chloride Sigma Aldrich Buffer 
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2.1.2 For RNAP assay 
Table 3. Chemicals used for RNAP assay 
Chemicals Company 
Adenosine 5′-phosphosulfate sodium salt Sigma Aldrich 
Alkaline Phosphatase, Calf Intestinal Fermentas 
Apyrase NEB 
ATP Determination Kit Biaffin GmbH 
ATP Sulfurylase NEB 
CTP, 100mM Solution Fermentas 
GTP, 100mM Solution Fermentas 
Manganese Chloride tetrahydrate Sigma Aldrich 
Ribonucleic Acid Polymerase from E. coli Sigma Aldrich 
Sodium Pyrophosphate Decahydrate Sigma Aldrich 
UTP, 100mM Solution Fermentas 
Rifampicin Sigma Aldrich 
Corallopyronin HZI 
Sorangicin HZI 
Ripostatin HZI 
 
 
2.1.3 For Pyrazinamidase assay 
Table 4. Chemicals used for PZase assay 
Chemicals Company 
α-Ketoglutaric Acid Sigma Aldrich 
Ammonium Iron (II) Sulphate  
Hexahydrate Sigma Aldrich 
L-Glutamic Dehydrogenase Sigma Aldrich 
Nicotinamide Fluka 
Nicotinic Acid Sigma Aldrich 
Pyrazinamide Sigma Aldrich 
Pyrazoic Acid Sigma Aldrich 
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2.1.4 Drug candidates from HZI (former GBF) 
Table 5. List of CP like substances 
Substances Name/Order Name Company 
Substance 16 CP14a HZI 
Substance 17 CP-17 HZI 
Substance 18 CP-18 HZI 
Substance 19 CP-19 HZI 
Substance 21 CP-21a HZI 
Substance 24 CP-24a HZI 
Substance 25 CP-25a HZI 
Substance 28 CP-28a HZI 
Substance 30 CP-30 HZI 
Substance 55 GW 387 HZI 
Substance 56 GW 386 HZI 
Substance 57 GW 389 HZI 
Substance 58 GW 341 HZI 
Substance 59 GW 342 HZI 
Substance 60 CP40 HZI 
Substance 61 CP 43 HZI 
Substance 62 CP 44 HZI 
Substance 63 CP45 HZI 
Substance 64 CP46 HZI 
Substance 65 CP47 HZI 
Substance 66 CP48 HZI 
Substance 71 GW414 HZI 
Substance 74 CP 57 HZI 
Substance 75 CP 58 HZI 
Substance 76 CP 59 HZI 
Substance 77 CP 60 HZI 
Substance 78 CP 61 HZI 
Substance 79 CP 63 HZI 
Substance 80 CP 64 HZI 
Substance 81 CP-66 HZI 
Substance 82 CP 68 HZI 
Substance 83 CP 69 HZI 
Substance 84 CP70 HZI 
Substance 85 CP65 HZI 
Substance 86 CP73 HZI 
Substance 87 CP74 HZI 
Substance 88 CP75 HZI 
Substance 89 CP76 HZI 
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2.1.5 Oligonucleotides 
Table 6. List of Oligonucleotides 
Primers for rpoA 
Name 5´-3´ Sequence No. 
rpoA-F CGAGTGCCCCCACAGACGTCATAT P581 
rpoA-R ATGTGAAGACGACCCGCCGA P584 
rpoA-HindIII-R GCGCGAAGCTTCTAAAGCTGTTCGGTTT P582 
rpoA-NdeI-F CTTATGACATATGCTGATCTCACAGCGCCC P583 
rpoA-NdeI-His-F CTGCATGCATATGCATCATCACCACCACCATCTGATCTCACAG
CGCCCCAC 
P639 
rpoA-HindIII-His-R AGGCAGTAAGCTTCTAGTGGTGGTGGTGGTGATGAAGCTGTTC
GGTTT 
P640 
 
 
Primers for rpoB 
Name 5´-3´ Sequence No. 
rpoB-Fw1 GCATCTTGGCAGATTCCCGC P436 
rpoB-Rv1 GCTTTACGCAAGATCCTCGACA P437 
rpoB-NdeI-His-F TTGGTCGCATATGCACCACCATCATCACCACTTGGCAGATTCC
CGCCAGAGCAAA 
P484 
rpoB-NdeI-F GGAAGGACATATGTTGGCAGATTCCCGCCAGAGCAAA P485 
rpoB-HindIII-R ATTTTGCGTTCGAATTACGCAAGATCCTCGACACT P486 
rpoB-HindIII-His-R- CCTAACAAGCTTTTAATGATGGTGATGGTGGTGCGCAAGATCC
TCGACA 
P488 
 
 
Sequencing primers for rpoB 
Name 5´-3´ Sequence No. 
rpoB+1074Fs GGTGGAAACCGACGACAT P451 
rpoB+2072Fs AGGCCGGTCAGGTGATCG P452 
rpoB+3067Fs TACATCATGAAGCTGCAC P453 
rpoB+2912Rs AACACCGGCGTCGACACAA P454 
rpoB+1921Rs TTTCTTCGGCGACGACGA P455 
rpoB+925Rs TATAGCGACCGACGCGGG P456 
rpoB+578Fs TGCACAGCGTCAAGGTGA P476 
rpoB+1829Fs  TGCCGCTGGTCCGTAGCGAGG P478 
rpoB+2581Fs  GAGCTGGTGCGTGTGTAT P479 
rpoB+3392Rs  CACCGTCACTCGATAGCA P480 
rpoB+2407Rs  TCAGCTCGGTCTCACCCTT P481 
rpoB+1404Rs TAGTGCGACGGGTGCACG P482 
rpoB+400Rs ACCGGTGTTGTTGTTGAT P483 
 
   
20 
Primers for rpoC 
Name 5´-3´ Sequence No. 
rpoC-F2 AACTGCGCGAAGGTGAGGAC P597 
rpoC-R2 TTGCCACTCATGTTGAACGG P595 
rpoC-NdeI-F TCCGTCGCATATGCTCGACGTCAACTTCTT P589 
rpoC-NdeI-His-F TTGGTCGCATATGCACCACCATCATCACCACGTGCTCGAC
GTCAACTTCTTCGAT 
P764 
rpoC-EcoRI-R GTCAGTGAATTCCTAGCGGTAGTCGCTGTA P587 
 
 
Sequencing primers for rpoC 
Name 5´-3´ Sequence No. 
rpoC-seqF-1 GTGCTCGACGTCAACTTC P733 
rpoC-seqF-401 ACGTGATCACCTCGGTCGA P734 
rpoC-seqF-802 TTCGACATCGACGCCGAA P735 
rpoC-seqF-1201 TCGCTTTCCGATCTGCTC P736 
rpoC-seqF-1604 ACTTCGACGGTGACCAGA P737 
rpoC-seqF-2007 CCGGGTGATGTTCAACGA P738 
rpoC-seqF-2401 ACCATCGTCGACTCCGGC P739 
rpoC-seqF-2803 AACGTCATCGTCGAGCGT P740 
rpoC-seqF-3213 CGGTGAGGAAGTGGTCTA P741 
rpoC-seqF-3617 TGCTGATGGGCATCACGA P742 
rpoC-seqR-3948 CTAGCGGTAGTCGCTGTA P743 
rpoC-seqR-3539 ATCAGCGAGCCAGGCAAA P744 
rpoC-seqR-3148 CGGTGACGTCGGCGATCG P745 
rpoC-seqR-2744 ATGTACGGGTCGCGGATCA P746 
rpoC-seqR-2345 TCGGTGGCTTCCTTCCAA P747 
rpoC-seqR-1948 ATAGCTCGGCCTCGATCT P748 
rpoC-seqR-1548 CACCAGCATTGGCTCGAA P749 
rpoC-seqR-1131 CACGGATTCCTGCAGCAT P750 
rpoC-seqR-734 TCGACGAGTTCGCGGTAGA P751 
rpoC-seqR-331 AGGGCACACCCTTGAAGT P752 
 
 
 
Primers for rpoZ  
Name 5´-3´ Sequence No. 
rpoZ-F CTAGTCAGTATTTAGCTTTCCA P591 
rpoZ-R2 ACTATTACCTGCTTGGGGAT P596 
rpoZ-NdeI-F CTGCATGCATATGAGTATCTCGCAGTCCGA P593 
rpoZ-NdeI-His-F CTGCATGCATATGCATCATCACCACCACCATAGTATCTCG
CAGTCCG 
P599 
rpoZ-HindIII-R AGACTTAAAGCTTCTACTCGCCCTCGGTGT P592 
rpoZ-HindIII-His-R CGCCTATAAGCTTCTAATGGTGATGGTGATGATGCTCGCC
CTCGGTGTG 
P600 
 
 
   
21 
Primers for pncA 
Name 5´-3´ Sequence No. 
pncA-F2 CGGCGTCATGGACCCTATA P603 
pncA-R2 GAACCCACCGGGTCTTCG P604 
pncA-NdeI-F TGGTGGACATATGCGGGCGTTGA P792 
pncA-Xho-SR GTTCGGCGCTCGAGTCAGGAGCTGCA P793 
pncA-Xho-SR GGCGGTGCTCGAGGGAGCTGCAAAC P794 
 
 
Sequencing primers for pncA 
Name 5´-3´ Sequence No. 
pnca-sF1 CATTGCGTCAGCCGTACT P633 
pncA-sF2 CCACCGATCATTGTGTGC P634 
pncA-sr1 GCAGCCAATTCAGCAGTG P635 
pncA-sr2 GGTCGATGTGGAAGTCCT P636 
 
 
Primers for amiD 
Name 5´-3´ Sequence No. 
amid-F2 CGGCGGCGCTGAAGTATCTGTT P785 
amidR2 ACCTTCGGTGCGACATTCGC P786 
amiD-NdeI-F TGATTAGCCATATGACCGATGC P790 
amiD-HindIII-R CGGCCGAGAAGCTTTCACACCGGCGG P791 
 
 
Sequencing primers for amiD 
Name 5´-3´ Sequence No. 
amiD727F ACGCTGCGGCGTATCGAAA P777 
amiD1130F GATTGTGCTTCGGCTCGA P778 
amiD1514F TCGACGTCAAGCTGCCCG P779 
amiD1930F CAGTTCATCGGCCGTGAA P780 
amiD1722R CGATCGCGTGAATTCCAG P781 
amiD1323R GACACTGAGCAATACCGC P782 
amiD907R TCGGGGCGTCGACCGTGTA P783 
amiD521R TTCGACACCGAACCGGAT P784 
 
Other sequencing primers 
Name 5´-3´ Sequence No. 
T7-promoter TAATACGACTCACTATAG P404 
T7-Terminator GCTAGTTATTGCTCAGCGG P406 
Rv2044cF TGGCGAATTGAACCTTTTCT P771 
Rv2044cR CACCCTCGCAGAAGTCGT P772 
TranspSF ACCGAAGAATCCGCTGAG P773 
TranspSR TCGCGTCGAGGACCATGGA P774 
pLEXSR-seq-F GGTGACCCCCGTTTCATC P637 
pLEXSR-seq-R GATGCCTGGCAGTCGATC P638 
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2.2 Instrument used 
Table 7. Instruments used 
Instrument Company Purpose 
Dark Reader Transilluminator Clare Chemical.com Blue Light to visualize 
DNA 
Dynex Microplate reader MRX 
Revelation 
 Dynex 96 well plate reader 
MRXTC Revelation  Dynex  96 Well plate reader 
POLARstar OPTIMA  BMG Labtech Luminescence 
Measurement 
Sigma Blotter Semi-dry Sigma Chemical Co. Blotter 
Sorvall RC-5B Refrigerated Superspeed 
Centrifuge 
 Sorvall Centrifuge 
Ultrasonicator Braun Biotech 
International GmbH 
Ultrasonication 
Fluor-S MultiImager Bio-Rad Agarose Gel 
Photography 
Millipore Multi Screen HTS-Vacuum 
Manifold 
Millipore Vacuum Accessory 
Vacuum Controller PVK 610 
(Vacu Box) 
MLT AG Vacuum Pump 
 
 
2.3 Software used 
Table 8. Softwares used 
Software and version Company Usage 
Vector NTI Advance 10 ver 
10.1.1 
Invitrogen Corporation Primer Design & Molecular 
Analysis 
Staden Package 
 Gap ver 4.10 
 Pregap 
 DNA sequence Analysis 
- DNA Alignment, Editing, 
Mutation Analysis 
FinchTV v1.4.0 Geospiza, Inc DNA Sequence Reading 
CellDesigner Systems Biology Institute Molecular Modelling 
SP 20000 ver 6.10.6.2 SAFAS monaco Reaction Kinetics Measurement 
Prism v 5.01 GraphPad Enzyme Characterization 
Bioworks package v 3.5 Beckmann Instruments, Inc Biomek 2000 Roboter 
MDL ISIS/Draw 2.5 MDL Information Systems, Inc Drawing Chemical Reactions 
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2.4 Bacterial strains and culture procedures 
2.4.1 Bacterial strains 
Table 9. E. coli strains used in this study. 
E. coli strain Genotype and relevant phenotype Reference 
E. coli Tuner (DE3) F- ompT hsdSB (rB 
- mB -) gal dcm lacY1 (DE3) 
Novagen 
E. coli BL21 (DE3) F- ompT hsdSB (rB- mB -) gal dcm 
(DE3) 
Novagen 
E. coli Nova Blue endA1 hsdR17(rK12 
- mK12+) supE44,thi-1 recA1, 
gyrA96 relA1 lac[F´proA+B+ , 
lacIqZM15::Tn10(TcR)] 
Novagen 
E. coli DH5 supE44 lacU169(80 lacZ 
M15), hsdR17 recA1 endA1 
gyrA96 thi-1 relA1 
(Hanahan 1983) 
E. coli Top 10F´ F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80lacZΔM15 ΔlacX74 recA1 
araD139 Δ(araleu), 7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
 
All Mycobacterium strains used in this study are listed in 
Table 10. Cell lysates and DNA from M. tuberculosis were kindly provided by Dr. W. Oehlmann (Lionex 
GmbH, Braunschweig, Germany). 
 
Table 10. Mycobacterial strains used in this study 
Mycobacterial Strain Code Origin 
M. bovis BCG Chicago ATCC 27289 DSMZ, Braunschweig, Germany. 
M. bovis BCG Copenhagen Danish strain 1331 Statens Serum Institut, Copenhagen, 
Denmark. 
M. marinum; DSMZ 44345 ATCC 11564 DSMZ, Braunschweig, Germany. 
M.smegmatis mc2 155 ATCC 700084 DSMZ, Braunschweig, Germany. 
M. tuberculosis H37Rv ATCC 25618 C. Espitia, Mexico City, Mexico. 
 
 
2.4.2 Cultivation of E. coli 
E. coli DH5 and  E. coli Top 10 F´ were used for transformation and propagation as 
well. The strain E. coli BL21 (DE3) was used for the expression of recombinant protein 
under the control of the T7 RNA polymerase promoter. The E. coli Tuner (DE3) and E. 
coli Nova Blue were also used for  expression of RpoB. The E. coli cells were cultured 
at 37 °C in LB medium on a rotary shaker operated at 160 rpm (INFORS AG), in 
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Erlenmeyer flasks filled up with not more than 20 % of their total volume. For strains 
with plasmids, selection was done by supplementing the medium with appropriate 
antibiotics either 100 μg/ml ampicillin or 50 μg/ml kanamycin. 
 
Table 11. Composition of LB Medium 
Tryptone (BD 211705) 10.0 g 
Yeast Extract (BD 212750) 5.0 g 
NaCl 10.0 g 
Distilled water  up to 1 L 
  
Adjust to pH 7.4 with NaOH (per 1 L 1 ml 1M NaOH)
 
 
Alternatively for the purpose of auto induction of protein, APS Agar medium with 
appropriate antibiotics was used. 
 
Table 12. Composition of APS medium 
Difco Select APS Super Broth 49.1 g 
Glyerol 87% 5 ml 
Deionized Water fill upto 1 L 
Check pH pH 6.8-7.5 
Agar 15 g 
 
Approximate Formula* per liter 
Soy Hydrolysate  12.0 g 
Yeast Extract 24.0 g 
Dipotassium Phosphate 11.4 g 
Monopotassium Phosphate 1.7 g 
*Adjusted and/or supplemented as 
required to meet performance criteria.  
 
 
2.4.3 Cultivation of Mycobacteria  
Culture conditions for M. bovis BCG, M. marinum ATCC11564 and M. smegmatis mc2 
155 were 37 °C in Middlebrook 7H9 broth (BD) with ADC enrichment (BD) or on 
Middlebrook 7H10 agar (BD) with OADC enrichment (BD). Liquid culture was done 
with moderate shaking of 160 rpm. For recombinant M. smegmatis mc2 155 and M. 
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bovis BCG, selection was performed by addition of 50 μg/ml kanamycin to the medium. 
Alternatively M. smegmatis mc2 155 was cultured in LB medium or LB Agar. 
Table 13. Composition of Middlebrook 7H9 broth 
Middlebrook 7H9 medium (1 L)  
Bacto-Middlebrook 7H9 Broth 4.7 g 
Glycerol (87 % (w/v)) 2 ml 
Water up to  900 ml 
Autoclave and add 100 ml ADC Enrichment  
 
 
Table 14. Composition of Middlebrook 7H10 agar 
Middlebrook 7H10 agar (1 L)  
Bacto-Middlebrook 7H10 Agar Base 19 g 
Glycerol (87 % (w/v)) 5 ml 
Water up to  900 ml 
Autoclave and add 100 ml OADC Enrichment  
 
2.4.4 Master cell bank 
Strains grown and selected in LB plates with antibiotics were used for temporary 
storage. The plates with clones can be used for a month when stored at 4°C. Glycerol 
stock was prepared for clones for a long term storage and stored at –20°C or –80°C. A 
master cell bank was made from the clones and preserved at –80°C for indefinite 
storage. 
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2.5 Plasmids used 
Table 15. Plasmids used in this study 
Plasmids Properties Reference 
pUC18 Cloning  vector (2.7 kb) containing portion of  pBR322 
and M13mp19, lacZα, pMB1 origin, bla, ampicillin 
resistant 
Fermentas 
(GeneBank accession 
number L09136) 
pET-22b(+) IPTG-inducible expression vector (5.5 kb), T7 promoter, 
T7 terminator, C-terminal His-tag, lac operator, pBR322 
ori, ampicillin resistant 
Novagen 
pET-26b(+) IPTG-inducible expression vector (5.4 kb), T7 promoter, 
T7 terminator, N-terminal His-tag, lac operator, pBR322 
ori, pelB coding sequence,  kanamycin resistant 
Novagen 
pET-28b(+) IPTG-inducible expression vector (5.4 kb), T7 promoter, 
T7 terminator, N-terminal His-tag with thrombin 
restriction site, lac operator, pBR322 ori, kanamycin 
resistant 
Novagen 
plexSR5 Modified pMV261 with hsp65 and kanamycin resistant. Lionex GmbH 
plexSR6 As plexSR5 except it contains additionally 
GCAATGGCCAAG after hsp65. 
             “ ” 
plexSR9 Modified pMV261 with hsp65, His and thrombin tagged 
and kanamycin resistant. 
             “ ” 
 
2.6 Methods of gene manipulation and analysis 
2.6.1 Isolation of plasmid 
2.6.1.1 Miniprep 
Miniprep was done for the isolation of up to 20 µg of plasmid from 2-4 ml of culture.  
The isolation of plasmid was done with QIAprep Miniprep (Qiagen) and according to 
the manufacturer’s instruction. 
Briefly, a colony of candidate clone was incubated in 5 ml or 20 ml LB media overnight 
with appropriate antibiotic. 3 or 4 ml of the culture was pelleted in 2 ml microcentrifuge 
tube. The pelleted bacterial cells were resuspended in 250 µl of Buffer P1 
(Resuspension buffer) then lysed with 250 µl of P2 Buffer (Lysis buffer) containing 
NaOH by gently inverting the tube for 4-6 times. 300 µl of Buffer N3 (Neutralization 
buffer) was added to neutralize the effect of NaOH in lysis buffer and mixed gently by 
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inverting the tubes for several 4-6 times, followed by centrifugation at 13,000 rpm for 
10 min. The supernatant obtained was pipetted in QIAprep spin column supplied by the 
manufacture and centrifuged for 1 min to bind the plasmid on the membrane of the spin 
column. After flow-through was discarded, the spin column was washed with 0.5 ml 
Buffer PB (Equilibration buffer) and centrifuged and the flow-through was discarded. 
The column was washed again with 0.75 ml Buffer PE (Wash buffer) and again 
centrifuged. After the flow-through was discarded, the column was centrifuged once 
again to remove any residual buffer left, then the spin column was placed inside a clean 
microcentrifuge tube and 50 µl of elution buffer (10mM Tris-HCl, pH 8.5) was added at 
the centre of the membrane waited for a minute. The elution was done with centrifugal 
force generated with 1 min centrifugation. 
Mini-scale isolation of plasmid DNA was used for the preparation of recombinant 
plasmid for sequencing and retransforming. Qiagen miniprep was used according to the 
manufactures instruction for the isolation of the recombinant plasmid. 
 
Table 16. Composition of Buffer P1 (Resuspension buffer) 
Tris-Base 6.06 g 
Na2EDTA.2H20 3.72 g 
Water Up to 1 L 
pH adjusted to pH 8.0  
RNase A 100 mg 
 
Table 17. Composition of Buffer P2 (Lysis buffer)  
NaOH 8.0 g 
Water Up to 950ml 
20% SDS (w/v) 50ml 
 
Table 18. Composition of Buffer N3 (Neutralization buffer) 
Potassium Acetate 294.5 g 
pH adjusted to 5.0 with glacial acetic acid  
Water Up to 1000 ml 
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2.6.1.2 Maxi Prep 
When a larger quantity of plasmid was required e.g. for RNAP Assay, Maxi prep was 
done according to manufacturer’s instruction. With maxi prep up to 500 µg of plasmid 
can be gained at once. 
A colony of E. coli Top 10F´ with pUC18 was cultivated in 100 ml LB medium 
supplemented with 100 µg/ml ampicillin. The cell pellet was harvested at 6000 x g for 
15 min at 4°C. The pellet was homogenously resuspended in 10 ml Buffer P1 
(Resuspension buffer), then mixed thoroughly with 10 ml Buffer P2 (Lysis buffer) by 
vigorously inverting 4-6 times and incubated at room temperature for 5 min to lyse the 
cells. During the incubation time, QIAfilter cartridge was prepared by screwing the cap 
onto the outlet nozzle of the QIAfilter Maxi cartridge. After the incubation time was 
over, 19 ml of chilled Buffer P3 (Neutralization buffer) was pipetted and mixed 
thoroughly by vigorously inverting 4-6 times to neutralize the effect of lysis. The 
bacterial lysate was cleared by pouring the lysate into the barrel of the QIAfilter 
cartridge and incubating at room temperature for 10 min. The cap from the QIAfilter 
cartridge outlet nozzle was removed and gently inserted into the QIAfilter Maxi 
cartridge and the cell lysate was filtered into a 50 ml tube. 2.5 ml of Buffer ER as added 
to filtered lysate, mixed by inverting the tube for 10 times and incubated on ice for 30 
min. Qiagen-tip 500 was equilibrated by applying 10 ml of Buffer QBT and allowing 
the column to empty by gravity flow. The filtered lysate was applied to the QIAGEN-tip 
to bind plasmid to the resin. The QIAGEN-tip was washed with 30 ml of Buffer QC 
(Wash buffer) to remove unnecessary contaminants. Elution of bound DNA was done 
with 15 ml of Buffer QF (Elution buffer). The eluted DNA was precipitated by adding 
10.5 ml of isopropanol. The precipitated DNA was pelleted by centrifuging it at 15,000 
x g for 30 min at 4°C. Supernatant was decanted and the DNA pellet was washed with 5 
ml of 70% ethanol and centrifuged at 15,000 x g for 10 min. Once again the supernatant 
was decanted carefully. The pellet was air-dried and the DNA was redissolved in 500 µl 
of Buffer TE (10mM Tris-HCl, 1mM EDTA pH 8.0). 
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2.6.1.3 DNA preparation in 96 well plate 
When a large number of plasmids are to be isolated, 96 well plate DNA preparation was 
preferred. Bacterial cells were cultivated in 1.6 ml LB medium with 50 µg/ml 
kanamycin at 37°C in a 96 deep well plate covered with air permeable foil in 230 rpm 
rotating shaker (INFORS AG). The overnight grown cells were centrifuged at  1500 x g 
for 5 minutes to pellet the cells. The supernatant from the deep well was carefully 
decanted. The cell pellets were then homogenously resuspended in 80 µl of suspension 
buffer by vortexing vigorously. The cell suspension was then mixed with 80 µl of 
denaturation buffer. 80 µl of neutralization buffer was pipetted and shaken in microtiter 
plate shaker (IKA Werke GmbH & Co. KG) for a couple of minutes. The lysate was 
transferred in 96 well Multiscreen HTS Nucleic A or NA plate (Millipore) and suction 
was applied with Vacuum Controller PVK 610  (MLT AG) with another 96 well 
Multiscreen HTS, FB or FB plate (Millipore) below the NA-plate in Millipore Multi 
Screen HTS-Vacuum Manifold (Millipore). The lysate passed from the NA-plate to FB 
plate during the suction. 150 µl of binding solution was pipetted in FB plate to bind the 
DNA. Washing was done with 200 µl of 80% Ethanol twice. The FB plate was dried at 
65°C for an hour. Elution was done with 35 µl water twice by applying the vacuum 
suction with another 96 well plate below FB plate. The first elution was done by wetting 
the FB plate at 37°C for a minute.  
Table 19. Composition of Suspension buffer (30 mM Glucose, 15 mM Tris-HCl pH 8.0, 30 mM 
Na2EDTA, 60 µg/ml Rnase A) 
1 M Glucose (Sterile Filtered) 6 ml 
0.3 M Na2EDTA 12 ml 
1 M Tris-HCl pH 8.0 3 ml 
RNase A (10 mg/ml) 12 µl 
MilliQ Water 179 ml 
Storage at 4°C.  
 
Table 20. Composition of Denaturation buffer (500 ml) Storage at RT 
5 M Sodium Hydroxide 20 ml 
10% SDS 50 ml 
MilliQ Water 430 ml 
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Table 21. Composition of Neutralization buffer (500 ml) Storage at RT 
Conc. Acetic Acid 70 ml 
5 M Potassium acetate 360 ml 
MilliQ Water 70 ml 
  
Table 22. Composition of Binding solution (6.1 M Potassium Iodide) 
Potassium Iodide 280 g 
MilliQ Water 196 ml 
Dissolve overnight, Store at RT protect from light. 
  
2.6.2  Polymerase chain reaction (PCR) 
PCR was performed in different volumes, 10 µl-100 µl according to the necessity. 10 µl 
was used for the optimization of a PCR e.g. during gradient PCR. For sequencing 
purpose 20 µl of PCR reaction was sufficient. For cloning purpose 50-100 µl of PCR 
reaction was used. For all individual PCR reactions, initial optimization of PCR was 
performed with gradient PCR. 
 
Table 23. Reaction composition using Taq DNA polymerase (Qiagen/Biomix) 
Component  Volume (µl) Final Concentration 
Taq PCR Master Mix  50 2.5 U 
Forward Primer 1 0.1 µM 
Reverse Primer 1 0.1 µM 
Distilled Water   
Template DNA  ≤ 1 µg/Reaction 
 
 
Table 24.  Reaction mixture for PCR using TaKaRa enzyme (total 100µl) 
Component  Volume (µl) Final Concentration 
TaKaRa LA Taq TM (5 U/µl) 1 2.5 U 
10x Buffer II 10  
Forward Primer 1 0.1 µM 
Reverse Primer 1 0.1 µM 
Template DNA  ≤ 1 µg/Reaction 
Distilled Water Up to 100  
Total 100 µl  
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Table 25. PCR reaction condition 
Denaturation  95°C 10 min  
Denaturation 95°C 30 sec  
Annealing 52 °C 30 sec 30x 
Extension 72°C X min*  
Final Extension 72°C 10 min  
Storage 4°C forever  
* Extension time depends upon the length of PCR product. For PCR products longer than 1kb, extension 
time of approximately 1 min per kb DNA was calculated. 
 
 
2.6.3 Agarose gel electrophoresis of DNA 
The size of DNA fragments or entire plasmids was determined by analysis on 0.8%, 1% 
or 1.5 % agarose gels. The lower the size of DNA the higher the percentage of gel used. 
The necessary amount of agarose was dissolved in 1x TAE buffer. DNA was loaded 
with an appropriate dilution in a 2 or 6-fold loading buffer (Fermentas) onto the gel 
using 1 x TAE as running buffer. The electrophoresis was performed at 80 - 100 Volts 
with Horizon 58 gel Chamber (Bethesda Research Laboratories) or DNA Sub Cell gel 
chamber (Bio-Rad ) for 30-45 minutes. The agarose gel was stained in a GelStar 
Nucleic Acid Stain (Lonza Verviers) in 1x TAE for 10 min. Photography of the agarose 
gel was done under UV light with Fluor-S MultiImager (Bio-Rad ). Alternatively for 
visualization and successive excision of DNA required for the extraction of DNA band 
from agarose gel, Dark Reader transilluminator (Clare Research) was used. 
 
Table 26. Composition of 50 x TAE buffer: 
Tris-Base 242 g 
Glacial Acetic acid 57.1 ml 
0.5 M EDTA (pH 8.0) 100 ml 
Water up to 1000 ml 
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2.6.4 DNA extraction 
2.6.4.1 With Qiagen Kit 
For small numbers of DNA, Qiagen Gel Extraction kit was used for the extraction of 
DNA of size less than 10 Kb. The kit can recover up to 10 µg of DNA. Plasmids 
restricted with restriction enzyme were also extracted with this kit. The kit was also 
used both for the extraction of PCR products or PCR products from the agarose gel.  
The DNA fragment was excised from agarose gel with a clean scalpel under blue light 
using Dark Reader transilluminator (Clare Research). The excised DNA fragment was 
weighed and 3 volume of Buffer QG was added to dissolve the agarose by incubating at 
50°C for 10 min in shaking Thermomixer 5436 (Eppendorf). After the agarose was 
dissolved 1 gel volume of isopropanol was added in the sample and mixed. The sample 
was applied in QIAquick column and centrifuged for a minute. The flow-through was 
discarded and the QIAquick column was washed again with 0.5 ml of Buffer QG. After 
1 minute centrifugation the flow-through was discarded. Final washing was done with 
0.75 ml of Buffer PE and after 1 minute centrifugation flow-through was discarded. 
Residual ethanol left in the column was removed by 1 min centrifugation. Elution was 
done in 1.5 ml microcentrifugation tube with 30 or 50 µl MilliQ water. 
 
2.6.4.2 PEG precipitation 
PEG precipitation method was used when DNA extraction from large number of 
samples was necessary. 20 µl of 10% PEG 8000 was mixed with 20 µl of PCR product 
in 96 well plate and mixed properly by vortexing. The plate with the mixture was 
incubated for 10 min at RT and then centrifuged at 3000 x g for 30 min at 4°C. The 
supernatant was carefully decanted by turning the plate upside down and gently tapping 
it. Complete removal of the supernatant was achieved by centrifuging the plate for a 
minute at 100 x g with the wells facing downwards. Washing of the pellet was done 
with 100 µl of 80% ethanol. The ethanol was decanted and the residual ethanol was 
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removed by centrifuging the plate for a minute at 100 x g with the wells facing 
downwards. The plate was air-dried and the pelleted DNA was solubilized in 10 µl of 
MilliQ water. 
 
2.6.5 Quantitation of nucleic acids 
2.6.5.1 Measurement of absorbance 
The qualitative and quantitative analysis of DNA was done with a UV 
spectrophotometer using a quartz cuvette. A nucleic acid solution containing 50 µg/ml 
of ds DNA has absorbance (Optical Density) of 1.0 at wavelength 260 nm. The 
concentration dependent absorbance of DNA at 260 nm was used to estimate the 
amount of DNA in a solution. DNA was diluted 1:10 or 1:100 with water. 100 μl of the 
solution was added into a quartz cuvette and absorbance was measured at 260 nm and 
280 nm against water as reference.  
Pure preparations of DNA and RNA have OD260/OD280 of 1.8 and 2.0 respectively. 
Qualitative analysis of DNA was controlled by calculating ratio of OD at 260 nm and 
OD at 280 nm if the solution contains pure DNA. If the measured ratio is smaller, it 
indicates a contamination. 
 
2.6.5.2 Quantitation in agarose gels 
Alternatively to the method described above, the concentration of nucleic acids was be 
approximated by staining the DNA in agarose gel with GelStar Nucleic Acid Stain 
(Lonza Verviers). A defined amount of GeneRuler™ 1 kb Plus DNA Ladder 
(Fermentas) was used as a standard to run a gel in parallel with the DNA in question. 
The gel was documented with a Fluor-S MultiImager (Bio-Rad ) and analyzed. 
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2.6.6 DNA sequencing 
Automated non-radioactive sequencing of DNA was carried out according to the di-
deoxy-method of Sanger (Sanger et al. 1977). The ABI PRISM Dye Terminator v3.1 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems) was used on a 3730xl 
DNA Analyzer (Applied Biosystems) according to the manufacturer’s instruction for 
DNA sequencing.  
 
2.6.7 DNA digestion with restriction endonucleases 
In each restriction reaction an amount of approximately 3 units enzyme (Fermentas) was 
used for each microgram of DNA. The amount of buffer (ionic strength) depended on 
the specific application, sought from the company’s website 
(http://www.fermentas.com). Restriction was done at 37°C for 2-4 hours. The 
inactivation of the enzyme depend upon the type of specific enzyme used. 
 
2.6.8 Ligation 
The molar ratio of insert to plasmid was approximately 3:1 was used for ligation. The 
reaction was carried out in a total volume of 20 µl in T4 DNA ligase buffer containing 1 
unit T4 DNA ligase (Invitrogen or Fermentas) per 1 µg DNA. The reaction mixture was 
incubated at room temperature overnight. 
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2.6.9 Transformation of DNA into bacteria 
2.6.9.1 Electroporation in E. coli 
Electrocompetent E. coli cells were prepared as follows:  
A single colony of E. coli was incubated overnight at 37°C at 160 rpm in LB broth to 
make a starter culture. From this starter culture 5 ml of the innoculum was inoculated in 
1 L of LB broth containing low salt concentration (10 gm tryptone, 5 gm yeast extract, 5 
gm NaCI per litre) and cultivated at 37°C with 160 rpm shaking. The cells were grown 
till the OD600 reached 0.5-0.9 (3-4 hours). The cells were then chilled on ice for 30 min 
and pelleted at 4000 x g at 4°C for 15 min. The pellet was resuspended and centrifuged 
for four successive washings. In the first washing 1000 ml of sterile cold water was 
used, in the second and the third washing 500 ml of sterile cold water was used and in 
the final washing 20 ml of sterile cold water was used. Finally dilution was done by 
resuspending the pellet in 2 ml of 10% sterile cold glycerol.  An aliquot of 40 µl of the 
electrocompetent cells were frozen at –80°C for future uses. 
For electroporation, 40 µl of the electrocompetent cells from –80°C were thawed in ice 
for 15 min. 1 µl plasmid (1 ng/µl in water) was mixed in chilled cuvette (E. coli Pulser 
cuvette, 0.2 cm gap; Bio-Rad). The cuvette was lightly tapped to mix and to settle down 
the cell mixture. Electroporation was done at 2.5 kV, 200 W and 25 μF with pulse time 
3-5 ms. The cells were incubated at 37°C for 30 min in SOC medium with moderate 
shaking and plated on LB Agar with appropriate antibiotics. 
 
Table 27. Composition of SOC Medium (SOB medium with 20 mM glucose) 
SOB Medium 1 L 
1 M glucose 20 ml 
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Table 28. Composition of SOB medium 
Bacto tryptone 10 g 
NaCl 0.5 g 
KCl 0.186 g 
Distilled water  up to 1 L 
 10 mM MgCl2* 
*Add 10 ml/L 1 M sterile MgCl2 just before use. 
 
2.6.9.2 Electroporation in M. smegmatis 
For electroporation of M. smegmatis mc2 155, 100 µl of the electrocompetent cells was 
used. Electroporation was carried out in room temperature. 10 µl plasmid (1 ng/µl in 
water) was mixed in precooled cuvette (E. coli Pulser cuvette, 0.2 cm gap; Bio-Rad). 
The cuvette was flicked to mix and settle cell mixture. Electroporation was done at 1.25 
kV, 800 Ohm and 25 μF for 9 ms as suggested by the Bio-Rad (Bio-Rad ). The cells 
were incubated at 37°C for 2 hour with moderate shaking and plated on LB Agar with 
kanamycin. 
 
2.6.9.3 Electroporation in M. bovis BCG Copenhagen 
For electroporation of M. bovis BCG Copenhagen 200 µl of the electrocompetent cells 
were thawed in ice for 15 min. 10 µl plasmid (1 ng/µl in water) was mixed in precooled 
cuvette (E. coli Pulser cuvette, 0.2 cm gap; Bio-Rad). The cuvette was flicked to mix 
and settle cell mixture. Electroporation was done at 1.25 kV, 600 Ohm and 25 μF for 9 
ms (Bio-Rad ). The cells were incubated overnight with moderate shaking and plated on 
Middlebrook 7H10 Agar with kanamycin. 
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2.6.9.4 Heat shock transformation 
Chemicompetent cells were prepared as follows: 
The method for preparing competent cells was a modification of the calcium chloride 
procedure. A colony of E. coli was picked and starter culture was grown overnight in 
LB medium.  The strain was further cultivated in LB medium with initial OD600 of 0.05. 
The cells were grown at 37°C with moderate shaking at 160 rpm until the OD600 
reached between 0.6 to 0.8 (log phase). 40 ml of the cells were pelleted by 
centrifugation at 3000 x g and resuspended in 20 ml cold 100 mM CaCl2 followed by 
incubation on ice for 20 min. The cells were recentrifuged and resuspended in 4 ml cold 
100 mM CaCl2 twice and incubated on ice for 1 hour. 200 µl of the bacterial suspension 
was aliquoted into pre-chilled tubes. The aliquots were either stored at –80°C for future 
use or used for heat shock transformation.  
A maximum of 3 µl of ligation reaction mix or 5 ng of pure plasmid was mixed gently 
with the competent cells for transformation. Incubation was done in ice for 30 min. Heat 
shock was done at 42°C for 45 sec followed by incubation of the cell in ice for 2 
minutes. 800 µl of SOC Medium was added to the tube to rejuvenate the heat stressed 
cells. The cells were incubated at 37°C for 30 min with moderate shaking. The cells 
after pelleting were resuspended in 100 µl SOC Medium and plated in LB agar with 
appropriate antibiotics for selection of antibiotics resistant clones. 
 
2.6.10 Selection of positive clones 
2.6.10.1 Colony PCR 
Colony PCR was done for the screening of the positive clones that grown in the LB 
plates supplemented with antibiotics in order to avoid the false negative clones. The 
same PCR condition described as before was used in order to amplify the inserted gene 
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from the recombinant E. coli except instead of DNA template colony of transformant 
was used. 
 
2.6.10.2 Auto induction 
A colony from transformants was streaked in LB plate with antibiotics and a replica in 
APS plate with antibiotics with a sterile toothpick. The LB plate was grown at different 
temperatures overnight.  Protein expressed from E. coli grown APS plates were 
analysed in SDS-PAGE and checked for the over-expression of protein. The positive 
clones were the one which over-express protein of specific size. 
 
2.7 Analysis of protein 
2.7.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE gel was done to check protein expression of clones or to check the purity of 
protein by separating the denatured proteins in electrical field.  SDS-PAGE was 
performed with Minigel System (11 cm x 7 cm x 0.1 cm) (Biometra) as described by 
Laemmli (Laemmli 1970). The protein sample was diluted 1:2 in 2X loading buffer 
denatured at 95°C for 10 min, cooled down and 1/10 volume of 1 M DTT was added to 
disrupt the disulphide bonding in the proteins. PageRuler™ Protein Ladder (Fermentas) 
was run parallel to the protein samples for comparison of molecular mass of the 
separated proteins. Electrophoresis was performed at 60 V till the proteins accumulate 
in the stacking gel. Later a potential difference of 120 V was applied for separating the 
proteins in the running gel.  
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Table 29. Composition of Stacking gels (4.0% gel, 0.125 M Tris, pH 6.8) 
  For 4 gels (ml) 
Distilled Water 6.15 
0.5 M Tris-HCI, pH 6.8 2.5 
20% (w/v) SDS 0.05 
Acrylamide/Bis-Acrylamide (30%/0.8% w/v) 1.34 
10% Ammonium Persulfate 0.05 
TEMED  0.01 
Total Monomer 10 
 
Table 30. Composition of 10% Separating gel in 0.375 M Tris-HCl, pH 8.8 
 For 4 gels (ml) 
Distilled Water 12.3 
1.5 M Tris-HCI, pH 8.8 7.5 
20% (w/v) SDS 0.15 
Acrylamide/Bis-Acrylamide (30%/0.8% w/v) 9.9 
10% Ammonium Persulfate 0.15 
TEMED 0.015 
Total Monomer 30 
 
Table 31.  Compositon of 15% Separating gel in 0.375 M Tris-HCl, pH 8.8 
 For 4 Gels (ml) 
Distilled Water 7.2 
1.5 M Tris-HCI, pH 8.8 7.5 
20% (w/v) SDS 0.15 
Acrylamide/Bis-Acrylamide (30%/0.8% w/v) 15 
10% Ammonium Persulfate 0.15 
TEMED  0.015 
Total Monomer 30 
 
 
2.7.2 Staining methods 
After running the gel, the gel was stained in coomassie blue solution containing 0.1% 
coomassie blue, 10% (v/v) acetic acid and 40%  (v/v) ethanol and 50% de-ionized 
water. The gel in the stain was microwaved for 1-2 minutes until it just started to boil 
and the stain was fixed for 15 minutes by shaking. After fixing the stain, the gel was 
destained with 10% ethanol to remove unnecessary background in the gel. The gels 
were heated in microwave to achieve fast destaining process. 
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2.7.3 Western blotting 
This is an analytical method for immunological detecting a specific protein. His-tagged 
protein was detected with this method. SDS-PAGE was used to separate denatured 
proteins. The separated proteins were then transferred to Immobilon  polyvinylidene 
fluoride (PVDF) microporous membrane (Millipore) to bind proteins.  
PDVF membrane was wetted in methanol and equilibrated in transfer buffer for 30 min. 
The SDS gel was also equilibrated in the same buffer. The transferring of the proteins 
from SDS gel to PDVF membrane was done at 15 V for 20-45 min in semi-dry Sigma 
Blotter.  After the proteins were transferred into the membrane, the membrane was 
incubated in blocking solution (1% BSA in 1xTBS, Tween 0.005%) in order to 
minimize any unspecific antibody binding to the membrane. The membrane was 
washed thrice for 5 min each in TBS- Tween (1xTBS, Tween 0.005%) and then 
incubated overnight with a dilution of 1:1000 – 1:5000 of the Anti-his Antibody in 
TBS-Tween. The membrane was again washed as described before and incubated for 
one hour with an horseradish peroxidase conjugated anti-goat Mouse IgG (Pierce) 
diluted 1:30,000 in TBS-Tween. The washing procedure was repeated before incubating 
the membrane with the substrate 3,3´,5,5´-tetramethylbenzidine (TMB) (Seramum 
Diagnostic GmbH) for HRP until a blue signal was developed. Reaction was stopped by 
rinsing the blot with water. 
 
Solutions used for Western blot 
Table 32. 10 X Transfer buffer (800 ml) 
Tris-Base 58 g 
Glycin 29 g 
SDS 3.7 g 
Water 800 ml 
 pH 8.3 
 
      
Table 33. 10 X TBS (1 L)  
NaCl 80 g 
KCl 2.0 g 
Tris-Base 61.0 g 
Water 1000 ml 
 pH 7.4 
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2.7.4 Determination of protein concentration 
Protein concentration was determined by the method of Bradford (Bradford 1976) using 
the Coomassie PlusTM Protein Assay Reagent (Pierce) against bovine serum albumin 
(BSA) as a standard. 5 µl of protein sample was mixed with 100 µl Protein Assay 
Reagent then incubated at room temperature for 5 minutes in 96 well plate microplate 
(Greiner). The absorbance was determined at OD595 with MRXTC Revelation (Dynex) 
using Revelation v4.25 (Dynex). The protein concentration of the samples was 
generated with Revelation v4.25 (Dynex) using a calibration curve with BSA as 
standard. 
 
2.7.5 N-terminal amino acid sequencing 
The protein of interest was separated by SDS-PAGE (2.7.1), transferred to an 
Immobilon PVDF-membrane (Millipore) and stained in a freshly prepared cold 
coomassie solution for a minute. The bands could be seen after destaining with 20% 
ethanol. The band of interest was cut with a clean sharp scalpel, washed in water and 
given for sequencing. The N-terminal amino acid protein sequencing was performed 
with the protein-sequencer 494 (Applied Biosystems). 
 
2.7.6 Gene expression 
2.7.6.1 Chemical induction 
Clone containing the gene of interest in pET vectors (Novagen) was grown in LB 
medium with specific antibiotics as a starter culture. The next day inoculation was done 
in 800 ml LB medium with 50 µg/ml kanamycin or 100 µg/ml ampicillin with the 
starting OD600 of 0.2. The cells were cultured for about 3 hours and checked for OD600. 
   
42 
When the OD600 reached between 0.6-0.9 induction was performed with 1 mM 
isopropyl-thio-β-D-galactopyranoside (IPTG) and further incubated at 30°C for 3 hr or 
overnight according to the induced protein, empirically determined from previous low-
scaled experiment. Harvesting of the cells was done by centrifuging the cell culture at 
5000 x g for 10 min and the pellets stored at –20°C for further applications. 
 
2.7.6.2 Auto induction 
Auto induction in E. coli BL21 (DE3) was done according to the proprietary  protocol 
from Lionex GmbH, Braunschweig, Germany. 3 ml of a suspension of starter culture 
cultivated in LB medium with appropriate antibiotics was spread in Qtray (Genetix) 
containing 200 ml APS medium with appropriate antibiotics to form a lawn culture, and 
the plates were incubated at different temperatures for 3-4 days. The bacterial layer was 
then scrapped with cell scrapper tipped with glass rod. 
 
2.7.7 Preparation of crude cell extract 
For work concerning protein, all procedures were carried out in cold condition or 
alternatively in ice. Cell pellet was suspended in buffer used for the equilibration of the 
column used for further purification at 5 ml per gram wet cell pellet mass. In case of cell 
pellet derived from APS medium, the pellets was first homogenized with Miccra D-9 
(ART-moderne Labortechnik) for 3 x 1 minutes (250 V ~50Hz, 80W, 3.6A, A= 10,500 
min-1) in appropriate volume of buffer because of smooth and sticky consistency of the 
cells, which do not readily allow the cells to suspend at ease. Cell lysis was performed 
by the mechanical ultrasonication (30 sec for 200 µl-1ml, alternatively 3 x 2.5 min for 
20 ml). A maximum of 20 ml was sonicated at a time. Cell lysate was decanted from the 
cell debris after centrifugation at 18,000 rpm for 15 min. 
Alternatively, when a large number of different cell extracts are required, chemical lysis 
with BugBuster Protein Extraction Reagent (Novagen) was done. It gently disrupts the 
cell wall of bacteria and liberates soluble protein without denaturing it. Streaks of cell 
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previously grown in APS medium for 3 days at 18°C was put in the wells of 96 well 
plate. The cells were suspended and subsequently lysis was done in 100 µl of BugBuster 
solution by shaking the plate in microtiter plate shaker (IKA) for 20 min. 
 
2.7.8 Protein chromatography 
For all chromatographic operations the FPLC systems BioLogic Workstation (Bio-Rad ) 
and Pharmacia LKB system (Pharmacia) were used. All buffers were filtered through 
0.2 μm membrane filter (Sartorius), subsequently degassed under a negative pressure. In 
all the purification processes, the column was first equilibrated with at least two column 
volume of buffer and then only the sample was loaded. Washing of the column was 
done with two column volume where necessary as in the case of Ni-NTA and Q-
Sepharose, where the protein was bound to the column material. 
 
2.7.8.1 Immobilized-metal affinity chromatography (Ni-NTA) 
The purification of 6 x His-tagged recombinant proteins were carried out with Ni-NTA 
Superflow resin (Qiagen). As per the manufacture, it has ability of absorbing 5-10 mg 
per ml of resin. Elution of the bound protein was done with buffer containing 500 mM 
Imidazole. Different strategies like linear gradient (5 ml Ni-NTA resin) or batch elution 
(50 ml Ni-NTA resin) were used for the elution of bound protein. 
 
2.7.8.2 Ion exchange chromatography Q-Sepharose 
15 ml Q-Sepharose (GE Healthcare) in XK16 column (Amersham Bioscience) was used 
for ion exchange chromatography. The column was equilibrated with 150 ml of 50 mM 
Tris-HCl pH 7.8. Sample was loaded into the column, and then washed with 250 ml of 
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the same buffer. The proteins were eluted with a linear gradient of 0-100% of 50 mM 
Tris-HCl, 500 mM NaCl pH 7.8. 
 
2.7.8.3 Desalting and buffer exchange 
The buffer of protein solutions was changed by gel filtration using a 150 ml Sephadex 
G-25 (Amersham Bioscience) in XK50 column. For small amounts of protein, desalting 
was done in Hi Trap Desalting 5x5 ml column (Amersham Bioscience). 10 mM 
ammonium bicarbonate buffer was used for the buffer exchange. 
Alternatively for buffer exchange, dialysis was performed twice. The first dialysis was 
done for 4 hours and the second dialysis overnight in a desired buffer. The molecular 
weight cut off of the membrane used depends upon the size of protein.  
 
2.7.8.4 Protein concentration 
For the concentration of small amount of protein Vivaspin 6, Vivaspin 20 and Vivacell 
70 (Sartorius) were used. The appropriate molecular weight cut off was chosen 
specifically according to protein size for each protein. Alternatively, for a larger volume 
of protein concentration was done in PALL concentrator with stirrer was used. Pressure 
up to 2.5 bar with nitrogen was applied with stirring condition at 4°C till appropriate 
volume was reached. 
 
2.7.8.5 Gel permeation with Sephadex G-25 
For desalting and changing buffer of large quantity of protein, Sephadex G-25 
(Amersham Biosciences) in XK50 column was used. While for small quantity HiTrap 
Desalting 5x5ml packed with Sepahdex G-25 Superfine column was used.  
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Sephadex is a bead-formed gel prepared by crosslinking dextran with epichlorohydrin. 
Gel filtration separates molecules according to their relative sizes. Sephadex G-25 has a 
fractionation range for globular proteins of 1000–5000 molecular weight. Large 
molecules are totally excluded while smaller sized molecules enter the beads to varying 
extents according to their sizes. Large molecules thus leave the column first followed by 
smaller molecules in the order of their decreasing size. 
 
2.7.8.6 Gel filtration on a Superdex 200 
Gel filtration with Superdex (Amersham Biosciences) provides the buffer exchange and 
separation of protein according to the size and thus the estimation of the protein size. A 
protein sample previously concentrated was applied in the volume of 2-5 ml in pre-
equilibrated column. The proteins were separated according to their sizes.  
 
2.8 Microbiological methods 
2.8.1 Kirby-Bauer method for antimicrobial sensitivity testing 
The Kirby-Bauer method known as the disk diffusion test was used for testing the 
efficacy of the test substances against E. coli DH5α. E. coli DH5α was grown to OD600 
0.2 and a 2 ml of the culture was evenly spread on the surface of solid LB agar in Qtray 
(Genetix) and wait for 5 minutes to dry the plate.  UV-sterilized assay disc (Schleicher 
& Schuell) of Φ 6 mm were placed above the agar plate. 10 µl of test solution was 
impregnated with 100 µg/ml or 10 µg/ml concentration on the surface of the disc. The 
substance diffused through the media away from the disk creating a concentration 
gradient. The plates were incubated at 37°C overnight. A clear retardation of growth 
around the test substance disc represents the zone of inhibition and represents the 
sensitivity to the impregnated substance.  
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2.8.2 Resazurin microtiter assay 
Resazurin microtiter assay (REMA) was carried out as described (Palomino et al. 
2002)).  
The assay was performed in 100 µl of Middlebrook 7H9 media supplemented with 
ADC enrichment (BD). A dilution of 1:3 was done in adjacent wells in the plate to yield 
different concentration of the test substance. Growth controls with solvent and sterility 
control without innoculum were also included in each plate. The innoculum was 
prepared from growing cultures of M. marinum ATCC 11564 from whic h turbidity was 
adjusted to 1/20 of McFarland. 100 µl of the innoculum was added to each 100 µl of the 
medium with test substance. The plate was covered, sealed in a plastic bag and 
incubated at room temperature in normal atmosphere. After 7 days growth of the 
organisms were measured in 96 plate reader then 30 µl of 0.01% sterile resazurin 
solution was added to each well, and the plate was reincubated overnight. A change in 
colour from blue to pink due to reduction of resazurin into resorufin indicated bacterial 
growth. MIC was defined as the lowest concentration of the substance that prevented 
this change in colour.  
 
2.9 Biochemical methods 
2.9.1 Determination of RNAP activity 
2.9.1.1 Homogenous fluorescent assay 
Initially for the establishment of RNAP Assay, fluorescent assay as described by 
Kozlov (Kozlov et al. 2005) was attempted. RNAP polymerase reaction was done in 10 
µl mixture containing 20 mM Hepes, pH 8.0, 10 mM MgCl2, 1.5 mM MnCl2, 0.1 mM 
EDTA, 25 µM GTP or Um-pppG (Guanosine-5´-triphosphate-γ-(4-methylumbelliferyl)-
ester), 25 µM CTP, UTP, ATP or Um-pppA (Adenosine-5´-triphosphate-γ-(4-
methylumbelliferyl)-ester), 1-5 µg of E. coli RNAP, 1 µg pUC18 plasmid DNA for 2 hr 
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at RT. After incubation, 2 µl of 0.5 M 3-[(N-1,1-dimethyl-2-hydroxyethyl)amino]-2-
hydroxyp ropanesulfonic acid (AMPSO), pH 9.2, containing 0.1 U of alkaline 
phosphatase activity was added and incubation continued for 5 min followed by 
addition of 2 µl of 100 mM EDTA, pH 9.0. The samples were transferred to standard 
96-well plates and the fluorescence was measured at 460 nm upon excitation at 355 nm. 
Reaction was also proceed by varying reagent volume, reagent concentration and 
reaction time. 
 
2.9.1.2 New RNAP assay developed in this study 
DNA dependent RNA polymerase (RNAP) synthesises RNA incorporating nucleotides, 
which in turn release pyrophosphate (PPi). A new combination of RNA polymerase 
followed by PPi quantitation by a non-radioactive method was developed. The RNAP 
reaction mixture contained 1 µl of E. coli K-12 RNAP (1.1 mg protein/ml, 500-1500 
U/mg), 500 ng pUC18 plasmid DNA in 10 mM MgCl2, 1.5 mM MnCl2, 0.1 mM EDTA, 
50 mM NaCl, 20 mM Hepes, pH 8.0 and 25 µM of each NTPs (ATP, UTP, GTP and 
CTP). The mixture was incubated for 30 minutes at 37°C for RNAP to synthesize RNA. 
Similar reaction performed by Kuhlman (Kuhlman et al. 2004) for 30 min resulted in at 
least 90% maximal RNA synthesis. 
After 30 min of polymerization, 2 µl containing (50 mU) of apyrase was added in the 
reaction mix to degrade the residual NTPs present in the reaction mix, which may 
interfere in the final signal detection. The reaction was carried out for 10 min at 30°C. 
Deactivation of apyrase was done for 10 min at 85°C. Further adenosine-5´-
phosphosulfate (5 µM) and ATP Sulfurylase (30 mU) was added in the reaction mix to 
synthesise ATP from PPi produced during the polymerization by RNAP. This step was 
carried out for 10 min at 30°C during which ATP sulfurylase converts PPi to ATP at the 
expense of adenosine 5´ phosphosulfate. A final denaturating of the enzymes present in 
the whole reaction was performed at 85°C for 10 min. Finally net ATP produced during 
the whole reaction was evaluated with ATP kit (Biaffin GmbH). ATP energizes the 
conversion of luciferin to oxyluciferin generating visible light, which is measured with 
POLARstar OPTIMA (BMG Labtech). The relative light unit detected from a reaction 
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mix correspond to the amount of ATP present in a particular reaction mix, which again 
corresponds to the amount of PPi produced during the polymerization reaction of 
RNAP. 
 
Method for  the evaluation of inhibitory effect of substances  
The reaction mix containing 2 µl of E. coli RNAP in 10 mM MgCl2, 1.5 mM MnCl2, 
0.1 mM EDTA, 50 mM NaCl, 20 mM Hepes, pH 8.0 and 25 µM of each NTPs (ATP, 
UTP, GTP and CTP) was incubated along with 2 µl of the test substance in 18 µl 
reaction mixture for 5 minutes in ice so as to bind the potential target at the active site 
of β-subunit of RNA polymerase. After 5 minutes 2 µl of pUC18 plasmid (250 µg/ml) 
was added. The reaction was continued for 30 min at 37°C.  
 
2.9.2 PZase assay 
2.9.2.1 PZase assay of clinical strains of M. tuberculosis 
PZase activity of clinical isolates of M. tuberculosis was determined by Dr. Maria 
Helena SAAD, Fiocruz, Brazil) using a modified method described by Wayne (Wayne 
1974). In brief, a heavy loopful of mycobacterial culture freshly grown on Lowenstein-
Jensen medium was inoculated onto 5 ml of Dubos broth medium supplemented with 
100 µg/ml PZA and 2 mg/ml sodium pyruvate in a 16 x 125 mm glass tube with screw 
cap. After incubation at 37°C for 4 or 7 days (when negative at the fourth day the tube 
was incubated for three more days), 1 mL of freshly prepared 1% ferrous ammonium 
sulphate solution was added to each tube, and the presence of a pink band was assessed. 
M. tuberculosis strain H37Rv, which is susceptible to PZA and positive for PZase, was 
used as a positive control and M. fortuitum was used as negative control for the assay. 
Strains with phenotypic and genotypic discordant results were retested for PZA 
susceptibility and PZase activity.  
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2.9.2.2 Cell free PZase assay 
Enzymatic assay of PncA was done in 100 mM Glycine buffer pH 6.0 with 1-5 µM M. 
tuberculosis PncA, 25-500 µM PZA, and 1000 µM ammonium ferrous sulphate. The 
enzyme activity was monitored at 450 nm with UV mc2 Spectrophotomer using SP2000 
v6.10.6.2 (SAFAS, Monaco). The positive reaction was characterized by the increment 
of OD450 due to production of orange-red complex formed by reaction of POA and 
ammonium ferrous sulphate (Allen et al. 1953). 
 
Fig. 9. Schematic Diagram showing the principle of detection of PZase assay. 
 
 
 
2.9.2.3 Whole cell PZase assay with pncA mutants developed in this study 
PZase assay with recombinant pncA clones in E.coli (wild type and mutant)  was done 
by a modification as described by Wayne (Wayne 1974). The cells were grown 
overnight in LB media supplemented with 50 µg/ml kanamycin overnight.  They were 
inoculated in 2.5 ml LB media pH 5.5 supplemented with 50 µg/ml kanamycin & 100 
µg/ml PZA. They were grown from OD600 0.2 for 3 hrs at 37°C without shaking. 0.5 ml 
of 1% ammonium ferrous sulphate solution was added in each tube to view the result. 
The positive PZase reaction was observed by the development of orange-red colour in 
the media immediately after the addition of ammonium ferrous sulphate.  
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Alternatively in a micro scale experiment, 200 µl LB media supplemented with 
kanamycin and PZA was used in 96 well plate. 4 µl of overnight culture was used as 
inoculum and the plates were incubated at 37°C for 3 hours. PZase reaction was 
visualized by adding 40 µl of 1% ammonium ferrous sulphate solution. 
 
2.9.2.4 High throughput cell free PZase assay developed during this  study 
The pncA mutants in E. coli BL21 (DE3) were cultured in APS-Kan plates at 18°C for 3 
days. The cell mass was collected with a sterile toothpick in a 96 well plate. The cells 
were lysed with BugBuster (Novagen) or ultrasonication. Protein concentration of the 
samples were determined and the value was feed in Biomeck 2000 robot. The robot was 
programmed to pipette 10 µg of the protein from the samples in a 96 well plate 
containing 50 µl 100mM Glycine pH 6.0. PncA reaction was initiated by adding 50 µl 
of 100mM Glycine.HCl pH 6, containing 1 mM PZA and 2 mM ammonium ferrous 
sulfate. OD was measured at 450 nm with MRXTC Revelation (DYNEX) at the interval 
of 20 sec for 20 minutes. 
 
2.9.2.5 Coupled enzymatic amidase assay 
Coupled amidase (Nicotinamidase or Pyrazinamidase) assay was done as described by 
Boshoff (Boshoff and Mizrahi 1998). Briefly, the assay mixture consisted of 30 mM 
Tris-HCl pH 7.5 with 11 U glutamate dehydrogenase, 800 µM α-keto-glutaratic acid, 
160 µM NADPH, 300 µM PZA or 300 µM nicotinamide and 5 µM of protein in 750 µl. 
The reaction was started with substrate either nicotinamide or PZA. The enzyme 
activity was monitored at 340 nm with UV mc2 Spectrophotomer using SP2000 
v6.10.6.2 (SAFAS, Monaco). The positive reaction was characterized by the decrement 
of OD340 due to oxidation of NADPH to NADP. 
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Fig. 10. Systematic Representation of coupled enzyme assay of PZase. 
 
 
2.10  Bioinformatics 
2.10.1 DNA sequence analysis 
For the analysis of DNA sequences, the reading of raw sequence was done with 
FinchTV (Geospitza). BLAST at NCBI (http://blast.ncbi.nlm.nih.gov) was used for  
searching nucleotide sequences. 
 For the analysis of mutations, the DNA sequences obtained from the DNA sequencer 
3730xl DNA Analyzer (Applied Biosystems) were analysed using the Pregap v1.6 and 
Gap4 v4.11 of the Staden Package (Staden et al. 2000). 
 
2.10.2 Molecular modelling 
Molecular Modelling was done with CellDesigner ver 3.5.1 
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2.11  Crystallization trials 
Crystallization trials were done with the purified proteins in 96 well screen plates. The 
purified protein was concentrated up to 5-10 mg/ml. 2 µl of the purified protein was 
pipetted in the well of crystallization plate. The reservoir contains buffers. Buffers used 
were from Crystal Screen and Crystal Screen 2 (Hampton) was pipetted in the reservoir. 
Also Mosquito Nanodrop Crystallization robot  (TTP LabTech) was used for preparing 
the 200 nl protein drops on pre-filled crystallisation plates. In case of PncA, either 
protein alone or together with PZA (substrate) or POA (product),  were used in the well 
contains 65 µl of Buffers of PACT Suite (Qiagen) or JSGC+ Suite (Qiagen). The plates 
containing proteins and buffers were left in incubator at 20°C undisturbed. The plates 
were observed after a day, after a week and after a month under light microscope for the 
development of crystal. 
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3 Results 
Objective: Evaluation of  current assays for RNAP and PncA. 
 
 
3. 1.  RNA  Polymerase as drug target 
3.1.1 Evaluation of current fluorescent assay 
As one of a drug target the β-subunit of RNAP is well known. The fluorescent assay 
described by Kozlov (Kozlov et al. 2005) was attempted for establishing at HZI for 
screening of corallopyronin like substances. However with time it was realized that the 
assay was not so simple as it was reported. The main problems encountered were 
inability of RNAP to utilize substrate (modified nucleotide) and the self fluorescence of 
the substrate, which resulted in high background. Thus making it impossible to 
implement the assay, though the substrates were purified with HPLC. Therefore 
alternative assay for RNAP activity had to be established (see below). 
 
3.1.2 Development of novel RNAP assay using E. coli RNAP 
A pre-requisite for  HTS is a simple and robust assay for the drug target. Our logic for 
developing the new assays was based on the observation that  PPi is released during in 
vitro transcription of RNA. What we needed was an efficient and HTS compatible 
additional test that could quantitate the released  PPi without the use of a radioactive 
substance. Based on our knowledge of Pyrosequencing, we reasoned that  Sulfurylase 
could convert PPi to ATP, which in turn can be detected with the help of  standard 
luciferin / luciferase assay. Our strategy is shown diagramatically  below  in figure 9.  
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Principle of the new Assay: 
 
DNA + NTP    DNA + RNA + PPi 
 
       ATP    ADP + Pi 
 
PPi + APS    ATP 
 
ATP + Luc    Oxyluciferin + hν 
 
 
 
NTP= Nucleotides (ATP, UTP, GTP& CTP) 
PPi= Pyrophosphate 
APS= adenosine 5´ phosphosulfate 
Luc= Luciferin 
 
 
 
 
 
 
Fig. 11. Schematic diagram showing the principle of the new RNAP Assay developed in this study. 
 
 
RNA Polymerase 
ATP sulfurylase 
Apyrase 
Luciferase 
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3.1.2.1 Validity of the assay 
The assay was tested for the validity of method. First it was checked if the measurement 
of ATP alone could be done properly with the Luciferin-Luciferase system as the first 
standard method.  
ATP Measurement
0
200000
400000
600000
800000
1000000
1200000
1nm ATP 10nm ATP 100nm ATP 1µM ATP 10µM ATP
Concentration of ATP
R
LU
 
Fig. 12. Test of Luciferin-Luciferase system. RLU measured with defined concentration of ATP (1 nM to 
10 µM) with Luciferin-Luciferase System. The reaction mix contains various concentration of ATP from 
1 nM to 10 µM and Luciferin-Luciferase system.  
 
 
After the measurement of the ATP concentration gradient, the ability of ATP 
Sulfurylase to convert PPi to ATP was determined by using PPi as the substrate. In 
positive reaction 10µM of PPi was incubated with 5 µM adenosine-5´-phosphosulfate 
and 30 mU ATP Sulfurylase. PPi was excluded in the negative reaction. The reaction 
was carried out for 10 min at 30°C during which ATP sulfurylase converts PPi to ATP 
in expense of adenosine 5´ phosphosulfate. A final denaturating of the enzymes present 
in the whole reaction was performed at 85°C for 10 min. Finally net ATP produced 
during the whole reaction was evaluated with ATP kit. 
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Pyrophosphate Reaction
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Fig. 13. Test of pyrophosphate reaction with the Luciferin-Luciferase system. In the positive reaction PPi, 
was reacted with ATP sulfurylase, which was then subjected to Luciferin-Luciferase system and RLU 
values measured. Rifampicin contains rifampicin in the positive reaction. In negative reaction PPi was 
excluded and Zero was the blank value measured. 
 
As the test done with PPi reaction gives positive result, final RNAP assay was done 
with reaction starting from RNAP. The RNAP assay as a whole is a successive enzyme 
assay containing four different enzymatic reactions. 
The complete RNAP assay was already described in previous sections. 
RNA Polymerase Reaction
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Fig. 14. Positive reaction contain all reactants necessary for RNAP Assay. Rifampicin contained 
Rifampicin, a known inhibitor of RNAP. Negative reaction did not have DNA necessary for the 
transcription of RNAP and Zero was the blank well. 
 
The Fig. 15 shows the measurement of RLU upon in vitro transcription using pUC18 
DNA template and subsequent reactions. The controls without DNA or RNAP show the 
luminescence value of the controls lacking DNA or RNAP. Other negative controls 
done were exclusion of both DNA and RNAP or using heat denatured RNAP. With 
these negative controls also the RLU measured in RNAP assay was comparable to the 
negative controls where DNA or RNAP were excluded from the assay. 
Rif 1µg/ml Without DNA Without RNAP Positive
R
LU
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Fig. 15. RNAP Assay with Negative controls (without DNA or without RNAP) and known inhibitor 
Rifampicin. Luminescence signal detected at different conditions. Positive, complete reaction mixture; 
Rif 1 µg/ml complete reaction mixture with rifampicin 1µg/ml; Without DNA, complete assay excluding 
pUC18; Without RNAP, complete assay excluding RNAP. 
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Fig. 16. Time dependent increment of RLU value. 
 
The RNAP assay was tested by carrying out after various durations of transcription. A 
steady  increase of RLU value was observed. 
The RNAP assay was tested with rifampicin, corallopyronin, sorangicin and ripostatin, 
which are all known inhibitor of RNAP. The result showed that all of them inhibit the 
RNAP.  Fig. 17  shows the inhibiting effect on RNAP activity exerted by rifampicin and 
corallopyronin, typical inhibitors of RNAP, which was detected with the RNAP assay. 
The extent of inhibition was related to the concentration of inhibitor used. The majority 
of RNA synthesis on pUC18 is expected to originate at the bla promoter where the 5´ 
terminus with sequence pppGAUAAAUG (Kozlov et al. 2005). 
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RNAP Assay
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Fig. 17. Concentration dependent inhibition observed in RNAP assay. Rifampicin (RIF) at three 
concentrations and corallopyronin (CP) at three different concentrations are shown. 
 
3.1.2.2 Robustness of the assay 
The quality performance and the robustness of an assay is defined by the Z´-factor 
(Zhang et al. 1999), which is calculated from the assay signal-to-noise ratio and the 
signal to background ratio. The statistical measure for the robustness of the assays is 
defined by the following equation: 
||
33(
1´
)()(
)()(



 

Z  
where µ(+) and σ(+) are the mean SD for the positive reaction, respectively, and µ(-) and σ 
(-) are the mean and SD for the background signal, respectively, and the denominator 
term is the absolute value of the difference in the means of the two measurements. The 
maximum value of Z´ is 1 for an ideal assay, where the signal and background do not 
deviate from their mean value. For a practicable assay, value ≥ 0.5 are acceptable for 
high throughput library screening. The Z´ statistic is a general measure of assay 
robustness and is also applied to any other enzymatic or other assay.  
The Z´values calculated in the RNAP assay was in the range of 0.758  to 0.901. 
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Objective : Screening potential drug candidates using the optimized assay for RNAP. 
 
3.1.2.3 Screening potential drug candidates using the new assay for RNAP 
Result obtained from the assay including Z´-factor showed it to be suitable for 
determining RNAP activity for HTS. To optimize the assay for the HTS, robot Biomek 
2000 was used with software Bioworks package v 3.5 (Beckmann Instruments, Inc) to 
pipette the assay components in 96 well plate. The assay in 386 plate was technically 
limited due to the cross talk of adjacent walls when measuring luminescence value.  
Complete inhibition was taken for the RNAP assay where there was no inhibitors or 
other substance. Null inhibition was taken where RNAP did not polymerise in the 
reaction i.e. either without DNA or without RNAP or with heat inactivated RNAP. 
In each of the experiments three samples were used to determine the SD of the 
measurement.  
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Fig. 18.  Screening of drug candidates by the new RNAP assay. RNAP assay was performed with 
different substances at 100 µg/ml and 10 µg/ml along with positive control which was reaction with all 
substance, negative control where DNA was excluded and two rifampicin concentrations of 1 µg/ml and 
10 µg/ml as control of RNAP inhibition. The Y-axis shows the RLU measured after the reaction and at 
the X-axis the substances are shown. 
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Fig. 19. As described in the legend for Table 35, different substances were tested at a concentration of 
100 µg/ml and 10 µg/ml. Positive control was the reaction with all substance. DNA was excluded in 
Negative control. Rifampicin at a concentration of 1 µg/ml and 10 µg/ml were used as controls for RNAP 
inhibition. The Y-axis shows the RLU measured after the reaction and at the X-axis the substances are 
shown. 
 
 
Table 34. Comparisons of inhibition achieved observed by Kirby-Bauers method and RNAP assay 
method for the inhibition of known RNAP inhibitors. 
RNAP Inhibitors 
Zone of Inhibition in E. 
coli DH5 with 10µg 
Subst. (Disc Diffusion 
Method) 
RNAP Inhibition 
at conc. 1 µg/ml 
RNAP Inhibition at 
conc. 0.1 µg/ml 
Rifampicin 0-1mm 96% ± 10% 78% ± 10% 
Corallopyronin NA 96% ± 20% 47% ± 15% 
Sorangicin 0-2mm 78% 78% 
Ripostatin 0-2mm 80% 44% 
 
 
 
 
 
 
 
 
R
LU
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Table 35. Comparisons of inhibition observed by Kirby-Bauers method and the new RNAP Assay  for the 
inhibition of the test substances. 
Substances Name 
Zone of Inhibition 
in E. coli DH5 
with 10µg Subst. 
(Disc Diffusion 
Method) 
RNAP Inhibition at 
conc. 
10µg/ml 
RNAP Inhibition at 
conc. 
100µg/ml 
 
Substance 16 CP 14a 2-3mm 20% ± 1% 24% ± 3% 
Substance 17 CP-17 ≤ 3mm 21% ± 1% 26% ± 8% 
Substance 18 CP-18 ≤ 4mm 17% ± 3% 19% ± 3% 
Substance 19 CP-19 ≤ 4mm 16% ± 2% 18% ± 4% 
Substance 21 CP-21a ≤ 3mm 20% ± 5% 33% ± 5% 
Substance 24 CP-24a ≤ 4mm 20% ± 3% 25% ± 5% 
Substance 25 CP-25a 2-3mm 19% ± 2% 15% ± 2% 
Substance 28 CP-28a 2-3mm 19% ± 4% 20% ± 4% 
Substance 30 CP-30 1-2mm 18% ± 4% 20% ± 3% 
Substance 55 GW 387 1-2mm 18% ± 3% 20% ± 4% 
Substance 56 GW 386 1-2mm 17% ± 3% 22% ± 6% 
Substance 57 GW 389 1-2mm 23% ± 4% 37% ± 9% 
Substance 58 GW 341 ≤ 1mm 21% ± 5% 47% ± 12% 
Substance 59 GW 342 1-3mm 24% ± 5% 35% ± 7% 
Substance 60 CP40 ≤ 1mm 20% ± 4% 25% ± 1% 
Substance 61 CP 43 ≤ 1mm 20% ± 3% 42% ± 13% 
Substance 62 CP 44 ≤ 1mm 19% ± 3% 29% ± 3% 
Substance 63 CP45 ≤ 1mm 21% ± 2% 34% ± 7% 
Substance 64 CP46 ≤ 1mm 19% ± 3% 26% ± 7% 
Substance 65 CP47 ≤ 1mm 19% ± 2% 30% ± 8% 
Substance 66 CP48 0mm 22% ± 3% 31% ± 7% 
Substance 71 GW414 1-2mm 24% ± 3% 35% ± 7% 
Substance 74 CP 57 ≤ 1mm 85% ± 1% 68% ± 0% 
Substance 75 CP 58 ≤ 1mm 66% ± 2% 83% ± 1% 
Substance 76 CP 59 0-2mm 75% ± 0% 95% ± 3% 
Substance 77 CP 60 ≤ 1mm 76% ± 2% 100% ± 1% 
Substance 78 CP 61 ?mm 30% ± 1% 51% ± 3% 
Substance 79 CP 63 NA 53% ± 6% 84% ± 4% 
Substance 80 CP 64 1-2mm 7% ± 10% 41% ± 6% 
Substance 81 CP-66 NA 1% ± 2% -5% ± 5%  
Substance 82 CP 68 NA 35% ± 6% 10% ± 3% 
Substance 83 CP 69 NA 27% ± 8% 12% ± 5% 
Substance 84 CP70 NA 31% ± 9% 13% ± 13% 
 
From all the tested substance, the substances 74, 76 and 77 seemed to be promising 
candidates as these show reasonable inhibition of RNAP (85%, 75% and 76%, 
respectively at 10 µg/ml). These corallopyronin like substances might be potential 
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substances for the future optimization for the development of new drugs for rifampicin 
resistant M. tuberculosis. 
 
3.1.3 Attempt to reconstitute M. tuberculosis RNAP holoenzyme in vitro 
 
Objective: Attempt to reconstitute M. tuberculosis RNAP holoenzyme for use in drug 
screening. 
The results described above were all done using E.coli RNAP. One of the objectives of 
this work was to produce RNAP components of  M. tuberculosis in E.coli and then 
attempt to reconstitute the holoenzyme which could then be used for drug screening. In 
our view such an assay would be better suited  for drug development for M. tuberculosis 
in future. 
3.1.3.1 Cloning, expression and purification of RpoA, RpoB, RpoC and RpoZ 
The complete genes (rpoA, rpoB, rpoC and rpoZ) were amplified from M. tuberculosis 
H37Rv DNA using the PCR primer sets for the gene. The PCR products were cleaved 
and extracted which serve as DNA template for the next cloning primer.  Cloning 
primers containing restriction sites were used for the re-amplification, which were used 
for the ligation in pET vectors (Novagen). Transformants were selected in LB agar with 
appropriate antibiotics. The transformants with insert were determined by checking the 
over-expression of the protein in APS agar (auto induction). Alternatively transformants 
with insert were also determined by colony PCR. Nucleotide sequences of the insert in 
pET vector were determined by conventional DNA sequencing and the identification of 
the protein was confirmed by protein sequencing. All the genes were cloned with and 
without histidine tag. Histidine tagged RpoA, RpoB and RpoZ were purified using a 
series of chromatography from Ni-NTA affinity chromatography to Q-Sepharose ion-
exchange chromatography and finally with Sephadex-200 size exclusion 
chromatography. 
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Table 36. PCR condition for the amplification of rpoA (1044 bp). Qiagen Master Mix was used for the 
PCR. 
   
 95°C 10 min  
95°C 30 sec  
55 °C 30 sec 30x 
72°C 1 min  
72°C 10 min  
4°C forever  
 
 
       
A                     B 
Fig. 20 A. 1.5% Agarose gel showing PCR amplified product of rpoA (arrow shows expected size of 
1176 bp) from M. tuberculosis H37Rv. Lanes: 1, PCR product; 2, GeneRuler™ 1kb DNA Ladder. 
Fig. 20 B. GeneRuler™ 1kb DNA Ladder (Fermentas). 
 
The amplification of rpoA from M. tuberculosis H37Rv DNA was done which was at 
the expected size of 1176 bp as shown with an arrow in Fig. 20 A. 
        1       2 
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A                         B             
Fig. 21 A. SDS-PAGE of M. tuberculosis RpoA-His (C-terminal His-tagged) expressed in E. coli BL21 
(DE3).  Lanes : 1, Insoluble extract after 3 hours of induction with IPTG; 2, Soluble extract after 3 hours 
of induction with IPTG; 3, PageRuler™ Protein Ladder. Rpo expected size: 38.5 kDa (arrow). 
Fig. 21 B. PageRuler™ Protein Ladder (Fermentas). 
 
The expression of recombinant C-terminal histidine tagged RpoA was done which was 
at the expected band of 38.5 kDa as indicated with an arrow in Fig. 21 A.  
 
 
       
A                         B 
Fig. 22 A. Western Blotting of the M. tuberculosis RpoA-His. Lanes: 1, His-tagged M. tuberculosis 
RpoA-His (positive reaction shown with an arrow); 2, PageRuler™ Prestained Protein Ladder 
(Fermentas).  
Fig. 22 B. PageRuler™ Prestained Protein Ladder (Fermentas). 
 
1     2    3  
1       2    
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Fig. 22 A shows the result of western blotting to detect histidine tag. The result 
confirmed that the protein was histidine tagged as indicated with an arrow. 
 
 
       
A                         B 
Fig. 23. SDS-PAGE of purified M. tuberculosis RpoA-His from E. coli BL2 (DE3). Recombinant his-
tagged RpoA was purified with a series of chromatography starting from affinity chromatography (Ni-
NTA), ion-exchange chromatography (Q-Sepharose) and finally with gel exclusion chromatography 
(Superdex-200) to yield a homogenous protein of 38.5 kDa as indicated with an arrow in Fig. 23 A. 
Lanes: 1, Purified M. tuberculosis RpoA-His component; 2, PageRuler™ Protein Ladder (Fermentas). 
Fig. 23 B. PageRuler™ Protein Ladder (Fermentas).  
 
Recombinant his-tagged RpoA was purified with a series of chromatography starting 
from affinity chromatography (Ni-NTA), ion-exchange chromatography (Q-Sepharose) 
and finally with gel exclusion chromatography (Superdex-200) to yield a homogenous 
protein of 38.5 kDa as indicated with an arrow in Fig. 23A. 
 
Table 37. PCR condition for the amplification of rpoB (3519 bp). Takara LA was used for the 
amplification of rpoB. 
   
 95°C 10 min  
95°C 30 sec  
49 °C 30 sec 35x 
72°C 3.5 min  
72°C 10 min  
4°C forever  
 
1       2    
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A                              B 
 
Fig. 24 A. 1% Agarose gel showing PCR amplified product of rpoB from M. tuberculosis H37Rv 
(expected size of 3527 bp shown with arrow) . Lanes: 1, PCR product; 2, 100bp GeneRuler™ 1kb DNA 
Ladder Plus (Fermentas). 
Fig. 24 B. GeneRuler™ 1kb DNA Ladder (Fermentas). 
 
Similarly, amplification of rpoB from M. tuberculosis H37Rv DNA was done with 
Takara LA which was at the expected size of 3527 bp as shown with an arrow. 
 
 
        
                           A                                      B 
 
Fig. 25 A. SDS-Page of M. tuberculosis His-RpoB (N-terminal His-tagged) expressed in E. coli BL21 
(DE3).  Lanes: 1, PageRuler™ Protein Ladder; 2, Pre-induced soluble extract; 3, Pre-induced insoluble 
extract; 4, Soluble extract after 3 hours of induction with IPTG; 5, Insoluble extract after 3 hours of 
induction with IPTG; 6, Soluble extract after overnight of induction with IPTG; 7, Insoluble extract after 
overnight of induction with IPTG. 
Fig. 25 B. PageRuler™ Protein Ladder (Fermentas). 
 
  1       2       3        4       5        6     7  
1       2    
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Expression of recombinant RpoB was done in LB medium (Fig. 25 A) and in APS agar 
(Data not shown). In the Fig. 25 A, gene expression induced with IPTG was shown at 
two different time intervals; 3 hours after induction and overnight after induction. 
 
 
            
A                   B 
 
Fig. 26 A. Western Blotting of the M. tuberculosis His-RpoB tagged with His. Lanes: 1, Positive His-
tagged; 2, PageRuler™ Prestained Protein Ladder. 
Fig. 26 B. PageRuler™ Prestained Protein Ladder (Fermentas).   
 
The result of western blotting to detect histidine tag showed that the protein was 
histidine tagged as indicated with an arrow in Fig. 26 A. 
1       2    
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              A                          B                      
Fig. 27 A. Purified M. tuberculosis His-RpoB (N-terminal His-tagged) expressed in E. coli BL21 (DE3). 
Lanes: 1, PageRuler™ Protein Ladder; 2, Degradation product of M. tuberculosis His-RpoB; 3, Purified 
M. tuberculosis His-RpoB. 
Fig. 27  B. PageRuler™ Protein Ladder (Fermentas) 
 
Recombinant his-tagged RpoB was purified with a series of chromatography starting 
from affinity chromatography (Ni-NTA), ion-exchange chromatography (Q-Sepharose) 
and finally with gel exclusion chromatography (Superdex-200) to yield a protein of 130 
kDa as indicated with an arrow in Fig. 27 A. During the purification of this protein, 
degradation was main problem. The problem was solved by using buffer containing 
10% Glycerol.  
 
Table 38. PCR condition for the amplification of rpoC (3951 bp). Takara LA was used for the 
amplification of rpoC. 
   
 95°C 10 min  
95°C 30 sec  
52 °C 30 sec 30x 
72°C 4 min  
72°C 10 min  
4°C forever  
 
 
1       2      3 
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A                      B 
 
Fig. 28 A. 1% Agarose gel showing PCR amplified product of rpoC from M. tuberculosis H37Rv 
,expected size of 4280 bp (arrow). Lanes: 1, PCR product; 2, GeneRuler™ 1kb DNA Ladder Plus 
(Fermentas). 
Fig. 28 B. GeneRuler™ 1kb DNA Ladder Plus (Fermentas). 
 
Similarly, amplification of rpoC from M. tuberculosis H37Rv DNA was done with 
Takara LA, which was at the expected size of 4280 bp as shown with an arrow. This 
gene could not be amplified only with this particular kit.  
 
 
   
A         B 
Fig. 29 A. SDS-Page. M. tuberculosis RpoC expressed in E. coli BL21 (DE3) in APS medium. Lanes: 1,  
Auto induced soluble extract; 2, PageRuler™ Protein Ladder. 
Fig. 29 B. PageRuler™ Protein Ladder (Fermentas) 
 
1       2       
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The recombinant RpoC was expressed in APS kanamycin agar. The Fig. 29 A shows 
the induction of soluble fraction of the protein of expected size of 146.7 kDa as 
indicated with an arrow. 
 
Table 39. PCR condition for the amplification of rpoZ (333 bp). Qiagen Master Mix was used for the 
amplification of rpoZ. 
   
 95°C 10 min  
95°C 30 sec  
52 °C 30 sec 30x 
72°C 30 sec  
72°C 10 min  
4°C forever  
 
 
        
A                       B 
Fig. 30 A. 1% Agarose gel showing PCR amplified product of rpoZ from M. tuberculosis H37Rv. Lanes: 
1, PCR product; 2, 100bp GeneRuler™ 100 bp DNA Ladder (Fermentas). 
Fig. 30 B. 100bp GeneRuler™ 100 bp DNA Ladder (Fermentas). 
 
Amplification of rpoZ from M. tuberculosis H37Rv DNA was done which was at the 
expected size of 439 bp as shown with an arrow. 
 
1       2       
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                  A                        B 
Fig. 31 A. SDS-PAGE of M. tuberculosis RpoZ-His (C-terminal His-tagged) expressed in E. coli BL21 
(DE3) in APS medium at 18°C for 3 days.  Lanes :1, PageRuler™ Protein Ladder; 2, Insoluble extract ; 3, 
Soluble extract. 
Fig. 31 B. PageRuler™ Protein Ladder (Fermentas). 
 
The recombinant RpoZ was expressed in APS kanamycin agar. The Fig. 31 A shows the 
induction of soluble fraction of the protein of expected size of 12.6 kDa as indicated 
with an arrow. 
 
     
              A                                    B 
Fig. 32. A. Western Blotting of the M. tuberculosis RpoA-His. Lanes: 1, Positive His-tagged M. 
tuberculosis RpoZ-His; 2, Positive control; 3, PageRuler™ Prestained Protein Ladder  
Fig. 34 B. PageRuler™ Prestained Protein Ladder (Fermentas) 
 
The result of western blotting to detect histidine tag showed that the protein was 
histidine tagged as indicated with an arrow in Fig. 33 A. 
 
1         2         3 
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A               B 
  
Fig. 34 A. SDS-PAGE of purified M. tuberculosis RpoZ-His from E. coli BL21 (DE3). Lanes:1, Purified 
M. tuberculosis RpoZ-His component; 2, PageRuler™ Protein Ladder (Fermentas). 
Fig. 34 B. PageRuler™ Protein Ladder (Fermentas) 
 
 
Recombinant C-terminal his-tagged RpoZ was purified with a series of chromatography 
starting from affinity chromatography (Ni-NTA), ion-exchange chromatography (Q-
Sepharose) and finally with gel exclusion chromatography (Superdex-200) to yield a 
protein of 12.6 kDa as indicated with an arrow in Fig. 34 A.  
1         2      
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3.1.3.2 Reconstitution of  RNAP core enzyme 
The attempt to reconstitute M. tuberculosis RNAP from its subunits was based on a 
previously described method using E. coli RNAP subunits (Tang et al. 1995).  
 
3.1.3.2.1 Nondenaturing approach 
C-terminal his-tagged RpoZ or C-terminal his-tagged RpoA was purified partially with 
Ni-NTA column. The other components of the RNAP without histidin-tag were 
suspended in  Buffer A (20 mM Tris-HCl, 500 mM NaCl, 5 mM Imidazole pH 7.8), the 
cells were lysed by sonication and the lysate was cleared by centrifugation (18000 rpm 
for 10 min at 4°C). Reconstitution of RNAP was done with one partially purified 
components viz C-terminal his tagged RpoA or C-terminal his-tagged RpoZ and mixed 
with rest of the soluble fraction components in the molar ratio of RpoZ, RpoA, RpoB 
and RpoC  to 1:2:1:1. 
The reconstitution mixture was dialysed twice against 750 ml of Buffer C (50 mM Tris-
HCl, 200 mM KCl, 10 mM MgCl2, 10 µM ZnCl2, 1 mM EDTA, 5 mM 2-
mercaptoethanol, 20% Glycerol) for 4 hours and overnight. The resulting mixture was 
then incubated at 30°C for 45 min, and then cleared by centrifugation (18000 rpm for 10 
min at 4°C). The mixture was stored at –20°C. 
Reconstitution mix after dialysis was repurified in Ni-NTA column, then concentrated 
in Vivaspin 20 with 100 kDa MWCO to remove unbound His-tagged components from 
the protein solution. Buffer exchange was also done at the same time. 
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          A                     B 
 
Fig. 35. Reconstituted RNAP from mixture of RNAP components of M. tuberculosis. Lane 1: 
PageRuler™ Prestained Protein Ladder 
Fig. 35.B. PageRuler™ Prestained Protein Ladder (Fermentas). 
 
The reconstituted RNAP did not show any activity in the  RNAP assay as compared to 
the E.coli RNAP.  
3.1.3.2.2 Denaturing approach 
The partially purified RpoA or RpoZ tagged with histidine were used in conjunction 
with other subunits of RNAP. The cell mass which over express RpoA and RpoZ were 
suspended in  Buffer A and the cells were lysed by sonication and the lysate was cleared 
by centrifugation. The cell pellets (RpoC, RpoB)  were resuspended in Buffer D (8 M 
Urea, 50 mM Tris-HCl, 10 mM MgCl2, 10 µM ZnCl2, 1 mM EDTA, 10 mM DTT, 
10% Glycerol pH 7.8) to lyse the cells. The lysates were  centrifuged at 13000 rpm for 
15 min at 4°C. For the purpose of reconstitution partially purified component either 
RpoA or RpoZ was mixed with the rest of the fraction components in the molar ratio of 
RpoZ, RpoA, RpoB and RpoC  to 1:2:1:1. 
The reconstitution mixture was dialysed against 750 ml of Buffer C (50 mM Tris-HCl, 
200 mM KCl, 10 mM MgCl2, 10µM ZnCl2, 1mM EDTA, 5mM 2-mercaptoethanol, 
20% Glycerol) for 2 times. The resulting mixture were next incubated at 30°C for 45, 
and then cleared cleared by centrifugation (18000 rpm for 10min at 4°C). The mixture 
was stored at –20°C. 
1         2      
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Reconstitution mix after dialysis was repurified in Ni-NTA column, then concentrated 
in Vivaspin 20 with 100kD MWCO to remove unbound His-tagged components from 
the protein solution. Buffer exchange was also done at the same time. 
With the reconstituted RNAP, RNAP assay described at 2.9.1.2 was done. On 
comparison to E. coli RNAP, the reconstituted RNAP did not show any activity. 
 
3.1.4 Mutation analysis of rpoB in clinical strains of M. tuberculosis 
We also charcterised the clinical M. tuberculosis strains from Brazil regarding 
mutations in rpoB gene as described below 
The rpoB gene from the clinical strains of tuberculosis of 6 rifampicin resistant and M. 
tuberculosis H37Rv were amplified using primers rpoB-F1 and rpoB-F2. The PCR 
products of 3527 bp were extracted with PEG precipitation method. The samples were 
given for sequencing along with PCR primers and rpoB sequencing primers. The raw 
sequences were aligned and joined using Pregap v1.6 and Gap4.11 of the Staden 
Package (Staden et al. 2000). All rifampicin resistant contain mutation restricted to a 
69-bp region. As it would be unnecessarily to sequence the complete gene, only the 
initial (ca. 600 bp) and final part of rpoB (ca. 600 bp) was sequenced only with rpoB-F1 
and rpoB-F2. There was no mutation present at the beginning or ending of the gene 
except the nonsense mutation D184D in 10 strains.  
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Table 40. Nucleotide changes  detected in rpoB gene in clinical strains of M. tuberculosis. 
Strain No. RIF 
Sensitivity *
Position and mutation Amino acid level 
24 R 310 C>T, 526 C> T  D184D, H526Y 
37 R 1299 C>T, 1304A>T  514 F, D516V 
35 R 1303-4 GA>TT D516F 
25 R 1304A>T  D516V 
32 R 1333C>T H526Y 
33 R 1349C>T S531L 
57** S 310 C>T D184D 
8** S D516V D184D 
27** S D516V D184D 
31** S D516V D184D 
65** S D516V D184D 
73** R D516V D184D 
78** S D516V D184D 
82** R D516V D184D 
87** S D516V D184D 
89** S D516V D184D 
* Data provided from Dr. M.H Saad. 
** Complete rpoB gene not sequenced. 
 
3.2  Pyrazinamide resistance and pyrazinamidase 
Objective: Identify mutation in pncA gene which are responsible for pyrazinamide 
resistance. 
3.2.1 Mutation analysis of pncA in clinical strains of M. tuberculosis 
The pncA gene from the clinical strains of tuberculosis was amplified with pncA-F2 and 
pncA-R2 primers. The DNA fragment up to 454 bp upstream of pncA was amplified 
with primers Rv2044cF and Rv2044cR. The PCR products were extracted with PEG 
precipitation method (2.6.4.2) and subjected to DNA  sequencing. The raw sequences 
were aligned then joined using Pregap v1.6 and Gap 4.11 of the Staden Package (Staden 
et al. 2000).  
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The pncA gene of 24 out of 93 clinical strains contained mutations at different sites 
distributed throughout the pncA gene (Fig. 36). Four types of mutations were observed. 
Point mutations, insertion, transposase insertion and deletion which are shown in figure 
35.  
pncA-Mutation Annotation
561 bp
pncA
InsDel
InsV130EVDV
D49E or D49A
L158P L171RP69A
C72Y or C72R
L35PV7G T76P or T76I
M174V
 
Fig. 36. Schematic representation of mutations observed in 561-nt pncA gene of M. tuberculosis. Ins and 
Del represents insertion and deletion respectively. 
 
 
Point mutations were observed in 11 strains. All observed point mutations lead to an 
amino acid exchange.  Insertions (TCCTCGTC, GAGGTCGAT and CG) were observed  
between  position 192-93, 388-389 and 444-445 respectively in three different strains  
(Table 41
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Table 41.  The insert GAGGTCGAT  and TCCTCGTC leads to tandem repeat. The first 
insert lead to repetition of AGGTCGATG or GAGGTCGAT twice (Fig. 37)  and the 
second insertion lead to duplication of TCCTCGTC (Fig. 38) 
 
 
 
Fig. 37.  Insertion of AGGTCGATG at 388-389 in pncA gene  leading to tandem repeat of  
AGGTCGATG  or GAGGTCGAT. The insertion is shown in grey and the tandem repeat is underlined. 
 
 
 
 
 
 
 
 
 
Fig. 38. Insertion of TCCTCGTC at 192-193 in pncA gene leading to tandem repeat of  TCCTCGTC. The 
insertion is shown in grey and the tandem repeat is underlined. 
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Table 41. pncA mutation in M. tuberculosis isolates 
Strain 
No. 
Mutation in pncA Amino acid level PZA 
Susceptibility * 
PZase Activity 
* 
Mutation cited 
103 20 T>G V 7 G  R - This study 
25 146 A>C  D 49 A   R - This study 
37 146 A >C D 49 A  S + This study  
13 147 C>G; IS6110 at -30  nt D 49 E  S + This study 
47 146 A>C D 49 A   R - This study 
44 146 A >C D 49 A  R + This study 
92 
104 T>G 
L 35 R R - 
This study; 
(Mphahlele et al. 
2008) 
33 172-173 Deletion of 2 nt Frameshift  NA NA This study 
26 192-193 TATCCTCGTC Frameshift  R - This study 
32 192-193 TATCCTCGTC Frameshift  R - This study 
101 192-193  TATCCTCGTC Frameshift   R - This study 
82 214 T>C C 72 R  R - This study 
41 215 G>A C 72 Y  R - This study 
107 
226 A>C 
T 76 P R - 
This study; 
(Rodrigues Vde et 
al. 2005) 
3 
 227 C>T 
T 76 I S + 
This study; (Park et 
al. 2001) 
89 
388 AGGTCGATG 
 V130EVDV R - 
This study; 
(Rodrigues Vde et 
al. 2005) 
40 444-445  Insertion of 2 nt Frameshift  R - This study 
20 457 C>G  L 158 P  R - This study 
23 515 T>C  L 171 R  R - This study 
66 523 A>G M174V  R - This study 
 
R: Resistance, S: Sensitive. 
*  PZA Susceptibility and whole cell PZase activity tests were done in clinical strains of M. tuberculosis 
and the data was kindly provided by Dr. M . Helena (Brazil). 
 
 
In one strain, the IS-like element, IS6110 (X17348), was identified 31 nt upstream of 
the pncA gene. The sequence (1361 nt) contained the typical direct 3 nt repeats and 
inverted repeats (28 nt with 3 mismatched nt) at its extremities as described by Thierry 
(Thierry et al. 1990).  This element disrupted Rv2044c, a gene for conserved 
hypothetical protein located downstream of Rv2045c (lipT). None of the analysed 
strains had mutation in pncA gene promoter region even 454 bp upstream of pncA. 
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Interestingly,  none of the mutants reported in table 41 were detected in by Jureen 
(Jureen et al. 2008) in the strains studied in Stockholm, Sweden recently. Similarly, 
except one, none of the nucleotide changes detected in this study were reported by  
Jureen (Jureen et al. 2008) and  Mphahlele (Mphahlele et al. 2008). 
On comparing the mutation in the clinical strains of tuberculosis in pncA and rpoB 
genes, no clear association between these was be observed (Table 42) indicating that 
mutations in these genes arise independently.  
 
 
Table 42. Mutations in rpoB and pncA 
Strain 
No. 
RIF* PZA* PZase* Mutation pncA Mutation rpoB** 
24 R R Pos No Mutation D184D, H526Y 
37 R R Pos D49A F514 F, D516V 
35 R R  No Mutation D516F 
25 R R Neg D49A D516V 
32 R R Neg Frameshift H526Y 
33 R R  Frameshift S531L 
73 R R Neg No Mutation D184D*** 
82 R R Neg C72R D184D*** 
87 S R Pos No Mutation D184D*** 
89 S R Neg V130EVDV D184D*** 
8 S S Pos No Mutation D184D*** 
27 S S Pos No Mutation D184D*** 
31 S S Pos No Mutation D184D*** 
57 S S Neg No Mutation D184D*** 
65 S S Pos No Mutation D184D*** 
78 S S Pos No Mutation D184D*** 
RIF: Rifampicin susceptibility, PZA: Pyrazinamide susceptibility, PZase: PZase Assay. R: Resistant, S: 
Sensitivity. 
* Data provided from Dr. M.H Saad. 
** The numbering used according to convention used for numbering E. coli rpoB. 
*** Complete data of rpoB not available. 
 
 
 
 
Previous published observation are further confirmed by the results presented in 
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Table 41 (see strains 25, 37, 44 and 47) which show that the whole cell mycobacterial 
PZAse assay does not correlate  strongly to the standard antibiotic testing in media 
containing PZA. This assay further suffers from the reduced growth rate of M. 
tuberculosis under acidic environment. 
We decided to take an alternative approach to solve this problem. We hypothesized that  
if the PncA (PZAse) of  wild type and mutants could be cloned and expressed easily in 
E.coli followed by measurement of enzyme activity, it could be developed as a standard  
assay which even could be further improved for HTS use. The results described below 
were obtained from experiments performed with this  objective. 
 
3.2.2 Cloning, expression and purification of PncA 
The complete genes pncA was amplified from M. tuberculosis H37Rv DNA using 
pncA-F2 and pncA-R2 primers (table 43, Fig. 39). The PCR products was cleaved and 
extracted which serve as DNA template for the next cloning primer.  Cloning primers 
containing restriction sites (pncA-NdeI-F and pncA-Xho+SR or pncA-Xho-SR) were 
used for the re-amplification, which were used for the ligation in pET vectors 
(Novagen). Transformants in E. coli BL21 (DE3) were selected in LB agar with 50 
µg/ml kanamycin. The positive transformants with insert were determined by checking 
the over expression of the protein of about 19.6 kDa in APS plate at 18°C for 3 days 
(Fig. 40 A). Nucleotide sequences of the insert in pET vector were determined by 
conventional DNA sequencing and the identification of the protein was confirmed by 
protein sequencing. The gene was cloned with and without histidine tag. Histidine 
tagged PncA was purified using a series of chromatography from Ni-NTA affinity 
chromatography to Q-Sepharose ion-exchange chromatography and finally with 
Sephadex-200 size exclusion chromatography (Fig. 40 B). 
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Table 43. PCR condition for the amplification of pncA (561 bp). Qiagen Master Mix or Bioline Master 
Mix was used for the amplification of pncA. 
   
 95°C 10 min  
95°C 30 sec  
57 °C 30 sec 30x 
72°C 50 sec  
72°C 10 min  
4°C forever  
 
 
 
  
A              B 
Fig. 39. 1% Agarose gel showing PCR amplified product of pncA from M. tuberculosis H37Rv. Lanes: 1, 
PCR product; 2, 100bp GeneRuler™ 100 bp DNA Ladder (Fermentas). 
Fig. 39. GeneRuler™ 1kb DNA Ladder Plus (Fermentas). 
 
Amplification of pncA from M. tuberculosis H37Rv DNA was done which was at the 
expected size of 561 bp as shown with an arrow. 
1         2      
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Fig. 40 A. SDS-PAGE of M. tuberculosis His-PncA (N-terminal His-tagged) expressed in E. coli BL21 
(DE3) in APS medium at 18°C for 3 days. Lanes: 1, PageRuler™ Protein Ladder; 2, Soluble extract ; 3, 
Insoluble extract. 
Fig. 40 B. SDS-Page of purified M. tuberculosis PncA from E. coli BL21 (DE3). Lanes: 1, Purified M. 
tuberculosis PncA; 2, PageRuler™ Protein Ladder (Fermentas). 
Fig. 40 C. PageRuler™ Protein Ladder (Fermentas). 
 
Similarly, amiD (another amidase)  gene from M. tuberculosis H37Rv DNA was also 
amplified and cloned in E.coli BL21 (DE3) as shown below. 
 
Table 44. PCR condition for the amplification of amiD (1428 bp). Qiagen Master Mix or Bioline Master 
Mix was used for the amplification of amiD. 
   
 95°C 10 min  
95°C 30 sec  
52°C 30 sec 30x 
72°C 1 min 50s  
72°C 10 min  
4°C forever  
 
 
1         2      1      2      
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A                 B 
Fig. 41. 1% Agarose gel showing PCR amplified product of amiD from M. tuberculosis H37Rv. Lanes: 1, 
PCR product; 2, 1Kb GeneRuler™ DNA Ladder (Fermentas). 
41 B. 1Kb GeneRuler™ DNA Ladder (Fermentas). 
 
       
 
 
Fig. 42 A. SDS-PAGE of M. tuberculosis amiD expressed in E. coli BL21 (DE3) in APS medium at 18°C 
for 3 days. Lanes: 1, Soluble extract; 2, Insoluble extract; 3,  PageRuler™ Protein Ladder. 
42 B. SDS-Page of purified M. tuberculosis PncA from E. coli BL21 (DE3). Lanes:  1, Purified M. 
tuberculosis PncA; 2, PageRuler™ Protein Ladder (Fermentas). 
 
3.2.3 Cell free PZase assay 
Direct enzymatic assay of PncA was developed based on Allen’s (Allen et al. 1953) 
description of formation of orange red complex during the reaction of POA with 
ammonium ferrous sulphate. This assay was tested with purified PncA enzyme.  
1      2      
1      2       3    
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Fig. 43. Absorption spectra of complex of POA and Mohr’s Salt. 
 
The characterization of pyrazinamidase  was done by measuring the absorbance of 
coloured complex formed from the product (POA) and Mohr’s salt at 450 nm. The 
initial velocity of the reaction was calculated with the initial slope (OD450/min) and the 
extinction coefficient of the POA and Mohr’s salt. These rates were applied for the 
kinetic parameter with GraphPad Prism v4.0.  
PncA reaction with 500 µM of PZA and 2 µg of PncA at 100 mM Glycine pH 6.0 was 
used for the calculation of the specific activity of PncA. A standard curve was prepared 
by treating different known concentrations of POA and Mohr’s salt in 100 mM Glycine 
buffer pH 6.0.OD450  measured during the kinetics of the assay after 2 min and 4 min of 
addition of PncA were converted to equivalents of POA by referring to the standard 
curve. It was observed that the specific activity of purified PncA was 10-11 U/µM. 1 U 
of pyrazinamidase was defined as the amount of PncA that produced 1 µM of POA per 
minute. 
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Table 45. Enzymatic characterization of the PncA 
Michaelis-Menten  
Best-fit values  
Vmax 357 
Km 232 
Std. Error  
Vmax 21 
Km 34 
95% Confidence Intervals  
Vmax 312 to 401 
Km 159 to 305 
Goodness of Fit  
Degrees of Freedom 16 
R2 0.9637 
Absolute Sum of Squares 5199 
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Fig. 44. Michaelis-Menten plot. Reaction rate (V0)  plotted against PZA concentration. 
 
The Km value for PZA 232 µM was comparable with other 300 µM (Boshoff and 
Mizrahi 1998). The high value shows a low specificity to the substrate. 
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Effect of pH 
 
The effect of pH in the enzyme assay was limited with this assay. An increment of the 
rate of reaction up to pH 6.2 was observed, however after 6.4 there was unusual 
character. It shifted down suddenly at this pH and tend to increase till pH 7.2 (Fig. 46). 
This could not be attributed only to the enzyme. Measurement of activity above pH 7.2 
was limited due to the precipitation of Mohr’s salt at this pH.  
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Fig. 45. Effect of pH on M. tuberculosis PncA. 100mM Glycine Buffers of different pH were used for the 
measurement.   
Effect of pH on PZase
4 5 6 7 8
0
100
200
300
pH
V 0
 [m
M
/m
in
]
 
Fig. 46. Abnormal character of PncA enzyme activity between pH 6.4 till pH 7.2. The pH characterization 
beyond pH 7.2 was not possible due to the precipitation of Mohr’s Salt. 
 
   
89 
0 2 4 6
0
200
400
600
800
1000
PZase [µM]
V 0
 [m
M
/m
in
]
 
Fig. 47. The increase of rate of reaction with increasing concentration of PncA. 
 
 
Thus, we could successfully establish an enzyme assay with the recombinant 
mycobacterial PZAse purified from from E.coli. In the next step similar attempts were  
made a series of pncA mutants. 
 
3.2.4 Cloning and expression of mutant PZase 
The DNA from clinical strains of M. tuberculosis containing mutation in pncA were 
used for the amplification of pncA gene with primers pncA-NdeI-F and pncA-Xho-SR. 
The DNA after extraction were cloned in E. coli BL21 (DE3) using pET-26b(+) and or 
pET-28b(+) vectors. The selection of the transformants was done in LB agar with 50 
µg/ml kanamycin. The positive clones were selected by checking the over expression of 
protein of about 19.6 kDa in APS agar with 50 µg/ml kanamycin. 96 well plate DNA 
preparation (2.6.1.3) was done from the positive clones and the plasmid extracted were 
sequenced for the confirmation of the clones and mutation, thus identifying the pncA 
mutants. 
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Fig. 48. Strategy used for the cloning of pncA mutants.  
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3.2.4.1 Cell free PZase assay with soluble lysate of the pncA mutants 
The recombinant pncA mutant clones  were cultured in APS agar with 50 µg/ml 
kanamycin in APS autoinduction medium. The bacteria were then suspended in either  a 
96 well plate or in a 96 deep well plate. The cells  in 96 well plate were lysed with 
Bugbuster, while the cell in 96 deep well plate was disrupted using ultrasonication.  
Supernatant fraction was separated from the lysate after centrifugation (3000 x g; 15 
min at 4°C). The protein concentration of the supernatant was determined. 10 µg of  
soluble cell extract was pipetted with Biomek 2000 in the micro plate containing 50 µl 
of 100mM Glycin pH 6.0; to which 50 µl of the mixture containing  1 mM PZA and 2 
mM ammonium ferrous sulphate 100 mM Glycine. HCl pH 6.0 was pipetted. The 
reaction was instantly measured with Dynex Microplate reader continuously at an 
interval of 20 sec for 20 minutes. 
 
 
Fig. 49. Result from high through output assay of cell free PZase assay. 10µg of cell extract of wild type 
(WT) and various mutants in the PncA reaction mix.  Two of the mutants had deficient PncA activity. 
 
The result from Fig. 49 show that mutations 147 C>G and 475 C>G lead a partial 
reduction in enzyme activity. Thus, by this method quantitative results for pncA 
(PZAse) of a mycobacterial strain  could be obtained within 2-3  days as compared to 
several weeks by currently standard methods.  
WT 
147 C>G 
475C>G 
Reaction mix without enzyme 
Negative PZase 
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Interestingly, the colour formation in microtiter wells could easily differentiate between 
positive and negative PZAse results (Fig. 50). 
 
 
 
Fig. 50. Microtiter plate wells showing the cell free PZase assay with pncA mutants (upper wells) and 
controls (lower wells).  
 
3.2.5 Development of a whole cell PZase assay with the recombinant pncA 
mutants 
Following the highly encouraging results obtained with the recombinant pncA clones in 
the cell free assay, we then attempted to develop an even more rapid and direct test for 
measuring pncA in recombinant E.coli strains. 
 
A preculture of pncA mutants in E. coli BL21 (DE3) was prepared from the overnight  
cultured clones in LB Medium with kanamycin. 100 µl from the overnight culture was 
used to inoculate 2.5 ml LB-medium pH 5.5 with 50 µg/ml kanamycin and 100 µg/ml 
PZA ml in a test tube. Alternatively 4 µl of the innoculum was used to inoculate 100 µl 
of LB-medium pH 5.5 with 50 µg/ml kanamycin and 100 µg/ml PZA ml in a 96 well 
plate. The initial OD600 in both case was approximately 0.02.  Incubation was followed 
at 37°C for 3 hrs. After 3 hrs, 0.5 ml of 1% solution was added in each tube containing 
2.5 ml culture and 40 µl of 1% ammonium ferrous sulphate solution was added in the 96 
well plate containing 100 µl of culture. With this assay, orange-red colouration was 
developed immediately after the addition of ammonium ferrous sulphate because the 
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POA produced by the cells is excreted into the medium. The PZase negatives could be 
clearly identified because there was no change in colour with the addition of ammonium 
ferrous sulphate (Fig. 50).  Assay done in test-tube with 2.5 ml of the culture media and 
200 µl in 96 microtiter plates were identical. As expected the colouration produced  in 
various mutant clones were of variable intensity showing variable degree of attenuation 
of the PZAse in different mutants (Fig. 50).  
 
 
 
Fig. 51. Whole cell PZase assay in liquid cultures. Media: medium only; pncA Mutant:  contains insert 
with mutation in pncA gene;  PncA clone and pncA clone 2  contain pncA wild type gene; amiD contains 
amiD; Empty clone contains only pET-26b(+) vector without any insert. The host strain was E. coli BL21 
(DE3) in all cases.  The  orange-red were PZase Positive. A mutant was slightly positive and Empty clone 
and amiD clone were PZase negative. Media was used for the control. 
 
A comparison of results obtained with the  the PZA resistant and sensitive strains from 
Brazil using the  standard mycobacterial PZAse assay and the new methods developed 
in this study are presented in table 46.  In addition, the results confirm that amid gene 
product of M. tuberculosis is unable to use PZA as substrate. Thus, as in M. bovis and 
M.bovis BCG, pncA is the only functional gene in M. tuberculosis coding for a 
functional PZAse. All strains of M.bovis reported till today are resistant to PZA due one 
single point mutation which completely inactivates the enzyme. 
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Table 46. Comparison of standard mycobacterial PZAse with the new methods developed in this study. 
 
Mutation in pncA Amino acid level 
Change it to 
OD after 10 
min 
PZase Assay 
with pncA 
Mutants * 
Cell free PZase 
assay with 
Soluble 
Fraction 
Mycobacterial 
PZase Assay 
** 
35A>G, 240C>T D 13 G, D 80 D 0,067 0 Negative  
100 T>C Y 34 H 0,044 0 Negative  
147 C>G D 49 E  0,108 4 Slightly positive Pos 
172-173  Deletion2bp Frameshift  0,04 0 Negative NA 
188 A>G D 63 G 0,044 0 Negative  
192-193  Insertion 8bp Frameshift  0,056 0 Negative Neg 
194 C>T, 241 T>A S 65 F, F81 I 0,055 0 Negative  
215 G>A, 515 T>C C 72 Y  0,032 0 Negative Neg 
226 A>C T 76 P 0,038 2 Negative Neg 
272A>G, 353A>G,515T>C E 91 G,  N 118 S, L 171 P 0,043 0 Negative  
281T>C, 515T>C F 94 S,L 171 P 0,03 0 Negative  
287 A>G K 96 G 0,048 0 Negative  
294C>T, 515C>T A 98 A, L171 P 0,044 0 Negative  
350T>C L 117 P 0,035 4 Positive  
355T>C W 119 R 0,059 0 Negative  
372-373 Insertion 9bp Frameshift  0,047 0 Negative Neg 
392T>A V 131 D 0,036 0 Negative NA 
444-445 Insertion 2bp Frameshift  0,045 0 Negative Neg 
475C>G L 158 P  0,051 1 Negative Neg 
507C>T V 168 V 0,055 § 5 Negative??  
Without any insert NA 0,072 0 Negative - 
With amiD NA 0,03 0 Negative - 
With other gene NA  0 Negative - 
Wild Type NA 0,184 5 Positive Pos 
E.coli BL21 (DE3) NA 0,032 0 Negative  
 
* Extent of colour production after addition of 1% ammonium ferrous sulphate. 0: No colour produced, 1 
to 5 increasing colour production. 
** Data provided from Dr. M.H Saad. 
§ Contains less amount of protein (Data not shown). 
 
 
The data presented in table 46 shows that the PZA assays developed in this study allow 
rapid decision about the PZA resistant or sensitive phenotype as compared to the 
conventional mycobacterial tests where it is often difficult to interpret the results. Only 
the 507C>T mutation gave unexpected negative result but on examination of the SDS 
gel it was noticed that the extract for this clone did not contain sufficient amount of 
recombinant protein.   
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3.2.6 Structural analysis of PZase 
The objective of the results described in this section was to find out whether the data 
obtained in this study on PZA resistant and sensitive strains from Brazil show a 
correlation between functional and structural features of pncA (PZAse). 
The M. tuberculosis PncA was subjected to a BLAST analysis against the Swiss-
Prot/TrEMBL database. (http://www.expasy.org/tools/blast/). The sequences were used 
for a further PRATT analysis to identify a conserved pattern within the achieved 
sequences.  
The pattern D-x-Q-x-[DT]-F-x(2)-[DGS]-[GS]-x-[AGLV]-[AGPST]-x(4)-[ADEGNQS] 
was identified. This pattern was found to be typical for the PncA protein family. Typical 
members of this family are PNC1 of Saccharomyces cerevisiae (P53184) and  
Pyrazinamidase/nicotinamidase of E. coli  (P21369).   
With Clustal alignment 10 absolutely conserved amino acids were identified among the 
PncA family. The result agree with the findings of  Du (Du et al. 2001). The identified 
conserved residues match well with the active site residues for P. horikoshii 
pyrazinamidase.  Du et al. proposed a catalytic mechanism, involving Lys94, Cys133 
and identified a zinc ion, crucial for catalysis.  
 
Table 47. Totally conserved  residues among the pncA family.   
M. tuberculosis S. cerevisiae P. horikoshii 
Asp8 Asp8 Asp10 
Gln10 Gln10 Gln12 
Asp12 Asp12 Asp14 
His51 His53 His54 
His71 His94 His71 
Lys96 Lys122 Lys94 
S104 S132 S104 
Leu120 Leu149 Leu115 
Gly132 Gly161 Gly127 
Ala134 Ala163 Ala129 
Cys138* Cys167* Cys133* 
* This AA is not completely conserved among all pncA proteins 
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Modelling was done with the Swiss Model server using the default parameters for the 
first approach mode. The model computed is based on the template of  the yeast 
nicotinamidase Pnc1p (PDB ID: 2h0r)  
The model  aligned very well with the P. horikoshii and S. cerevisiae nicotinamidase. 
The root square deviation, which measures the average distance between the backbones 
of superimposed proteins is 0.6 and 0.5 respectively. All residues of the active site of M. 
tuberculosis PncA, S. cerevisiae nicotinamidase and P. horikoshii enzyme are 
completely conserved and aligned completely.   
 
 
Fig. 52. Model of PZA located in the active site of PZase of M. tuberculosis. 
 
 
 
A model of  pyrazinamide was used to model the position of pyrazinamide in the active 
site (Fig. 52). PZA was positioned according the catalytic model of  Du (Du et al. 
2001). The oxygen of the carboxamide group was positioned between the amide groups 
of the main chain of Ala134 and Cys138 to form hydrogen bonds. The final position of 
the oxygen was modelled at the position of water 297 in the 2h0r. In the final model the 
oxygen of the carboxamide group forms hydrogen bonds to the main chain of Ala134  
and Cys138. No clashes between the PZA and the protein residues occur.  
   
97 
Based on  this model one can conclude that the active site is formed by Leu19 and 
Val163 to form a hydrophobic pocket for the PZA ring. Backbone amides of Ala134 
and Cys138 bind the oxygen of PZA. His71 and His51 bind Zinc, which has a crucial 
role in catalysis Du (Du et al. 2001). 
 
 
Fig. 53. Structural alignment of amidases from P. horikoshii (Red, PDB ID: 1IM5), M. tuberculosis 
(Green, Theoretical model) and  S. cerevisiae (Blue, PDB ID: 2h0r). The amino acid residues number 
convention followed corresponds to M. tuberculosis PZase. 
 
 
The catalytically important residues Cys138 and Ala134 act via main chain bonds. 
Therefore, a substitution with  an amino acid of the same size may not be detrimental 
for catalytic activity. His71 and His51 appear to be the  most important residues, due to 
their role in zinc binding.  
The analysis of PncA mutants presented in this study correlates well with the model 
discussed. 
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4 Discussion 
The two main problems concerning TB therapy today are, 
 
1. Long-term treatment which often leads to patient non-compliance resulting in 
the emergence of drug resistant TB which frequently is untreatable with current 
drugs, 
 
2. There are no drugs to treat persistent/dormant and XDR TB  
 
Rifampicin and Pyrazinamide are two highly useful first-line TB drugs with antibiotic 
activity against replicating and dormant M. tuberculosis, respectively.  Unfortunately 
resistance to these antibiotics is quite frequent. This problem of drug resistance can only 
be solved by intensive efforts in drug development which mostly rely on efficient assay 
system suitable for HTS of drug candidates. Current assays for RNAP (Rifampicin 
target)  and PZAse (Pyrazinamide target) are unsuitable for such use. 
Here we present two novel strategies for assaying RNAP and Pzase with a potential 
application in HTS for  drug development against M. tuberculosis and for the diagnosis 
of Rifampicin-  and/or PZA-resistant clinical strains of M. tuberculosis. 
 
4.1 RNAP  
Bacterial DNA-dependent RNA polymerase is an attractive drug target because RNA 
chain elongation is essential for bacterial growth (Jin and Zhou 1996). RNAP Assay can 
be used for screening chemicals which may lead to a hit for RNAP.  
The current assays for the activity of RNAP require the use of radiolabeled (Daniel et al. 
1975; McClure 1980; Wu et al. 1997) or chemically modified nucleotides like 
fluorescent derivative of nucleotide (Bertrand-Burggraf et al. 1984; Kozlov et al. 2005; 
Bhat et al. 2006) or other derivative of nucleotide (Vassiliou et al. 2000) or detection of 
end product of transcription like RNA (Kuhlman et al. 2004) or PPi (Johnson et al. 
1968). These  assays to monitor RNAP activity depend on the detection of radiolabeled 
RNA product synthesized during the transcription process. Most of the assays are gel-
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based in which radiolabeled RNA is visualized in gel electrophoresis or use scintillation 
counter. Although radioactive signals are easily detected and quantified, these methods  
have  disadvantages such as  user exposure to radiation, short shelf life, high handling 
cost for radioisotopes and high labour costs. The use of modified florescent nucleotides, 
on the other hand has not been successful as a routine assay. 
For a HTS, the use of live M. tuberculosis or strain extracts are  not appropriate, not 
only because it is an highly infectious organism, but also because it is an extremely 
slow growing bacterium. Thus, for an  HTS of drugs or drug candidates as inhibitors of 
RNAP of  M. tuberculosis,  there is an urgent need for a rapid and feasible assay.  
The purification of large quantity of native RNAP from M. tuberculosis is very labour 
intensive, hazardous and time consuming and cumbersome process. In an effort to 
improve the characterization of polymerization and develop new antibiotics that target 
RNAP, a nonradioactive assay was developed, which does not utilize radioactive or 
florescent nucleotides but can use natural nucleotides. A coupled-enzyme system based 
on E. coli RNAP and the luminescent detection of ATP by converting PPi using ATP 
sulfurylase through successive steps  was devised. The background of the reaction was 
lowered by using apyrase to degrade the residual nucleotides after the RNAP reaction 
prior to converting PPi to ATP. 
Although the RNAP Assay discussed is simpler than the classical radioactive test, also 
suffers from some draw backs as other test due to the multiple steps it has to pass 
through. In every step there is a danger that one of the other enzyme than RNAP may be 
affected by the substance tested which may or may not wholly affect the result, thus it 
might be necessary to include the substance as a control in case a hit is sought out. On 
the other hands, the light produced from luciferin and luciferase system varies according 
to the batch and the storage of the detection system. However this draw back can be 
tackled by using the controls every time and analysing the result in terms of controls. 
The other crucial process in the RNAP assay is the effect of temperature gradient, when 
incubating 96 well plate. This was solved by using a thermocycler for the purpose of 
incubation and denaturation of the enzyme. The measurement however should be 
carried out in a white plate. 
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The new assay developed in this work is simple, cost effective and easy to handle. Also 
the reagents required for the assay are all  commercially available. 
One of my objectives was to replace E. coli RNAP with M. tuberculosis RNAP 
remained unfilled. RNAP is a huge complex, which require at least three components 
viz. RpoB, RpoC and two RpoA to form functional enzyme. During the course of work, 
several methodologies were attempted to produce functional M. tuberculosis RNAP, 
however a functional RNAP as expected could not be produced, although other (Jacques 
et al. 2006) have shown to produce functional one. It is easy to understand that even if 
one of the component do not orient properly during the composition of the complex, it 
will not work.  
 
4.2 Pyrazinamidase  
The mechanism by which the PZA functions in the TB remains still incomprehensive 
though vast amount of research has been done. The PncA in M. tuberculosis is deemed 
to be responsible for the conversion of PZA to POA, which in turn acts in the 
Mycobacteria to kill the cells. The inhibition with POA in mycobacteria is still illusive 
whether it is due to general intercytoplamic acidification or due to inhibition of specific 
cellular target. The physiological role of the nicotinamidase in most prokaryotes is to 
degrade nicotinamide to nicotinic acid, which in turn is recycled to NAD via the Preiss-
Handler pathway of the pyridine nucleotide cycle (Foster and Moat 1980).  
Besides pncA, there are several other putative amidases like amiA1, amiA2, amiB1, 
amiB2, amiC and amiD. Concerning the resistance developed by M. tuberculosis BCG 
against PZA and the probable amidases present in both the M. tuberculosis BCG and M. 
tuberculosis H37Rv, alignment of the protein sequences of all these amidases show that 
only pncA contains mutation at 169 C>G (His57Asp) which can be accounted for the 
resistance it develops against PZA. During the sequencing of amiD gene from several 
strains, a novel mutation  at 220 G>T (Ala74Ser) was encountered, however due to its 
presence in both PZase positive and PZase negative as well as in  both PZA sensitive 
and PZA resistant strains. The M. tuberculosis AmiD was also not able to take PZA as a 
substrate.  
   
101 
A modification of Wayne’s method of determining the PZase activity of strains was 
performed in E.coli BL21 (DE3) mutants of pncA. In this assay the activity of the 
mutant could be accessed directly. PZA converted into POA was secreted in medium, 
which then react with ammonium ferrous sulphate to produce a red-orange complex.  
The same test with amiD was negative, conferring the inability of amiD to act on PZA.  
The excretion of amidase by M. tuberculosis in culture filtrate is already known 
(Raynaud et al. 1998). The  resistance developed by PZase positive organism like M. 
smegmatis may be due to the location of the enzyme. In M. tuberculosis the enzyme is 
found extracellularly in the culture filtrate while in M. smegmatis it is located deep 
inside the cell envelope (Raynaud et al. 1998), which can be accessed only after treating 
the cells with Tween 80 for 24 hours and glass beads. 
PZA susceptibility testing is difficult and often unreliable because of the acid pH 
requirement for drug activity (Hewlett et al. 1995). The problem of the susceptibility 
testing is the inhibition by acid such that at least 10% of clinical isolates cannot be 
tested because they fail to grow on the acid pH medium (pH 5.5) (Siddiqi 1992). The 
most common problem is false resistance which is caused by large inoculum of a 
sensitive strain (Hewlett et al. 1995). In our studies also we have encountered 
incompatibility of the data in the mutation (D49A) observed and the PZA susceptibility 
test. PZA susceptibility has also been determined by detecting PZase activity of cultured 
M. tuberculosis (McClatchy et al. 1981; Miller et al. 1996; Suzuki et al. 2002) since 
PZase activity is lost during PZA resistant isolates (Konno et al. 1959; Zhang and 
Mitchison 2003). However, the interpretation of classical PZase assay done according to 
Wayne’s method lacks a clear interpretation.  This is due to the instability of  
ammonium ferrous sulphate, which is the core reagent used for the development of the 
colour. At one hand it produces brown colour in alkaline pH at the other hand, the 
reagent itself is not stable for a long period of time. It slowly develops brown 
colouration with time even at 4°C within a week and at RT the reagent develops brown 
colouration within a few days. The clear interpretation of Wayne’s method is thus 
difficult because the Mycobacteria takes time to grow and the reagent to access the 
assay is not stable. At pH higher than 7.0, the reagent auto precipitates, thus rendering it 
unusable as a reagent at alkaline condition. 
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The M. tuberculosis pncA gene was cloned, over-expressed, purified to homogeneity 
and enzymatic characterization was done. It was also observed that the enzyme was able 
to take both PZA and nicotinamide (data not presented). The enzyme was found to have 
an activity of 10-11 U/µM. The exclusion of PncA during the purification of size 
exclusion chromatography showed it to be a monomer.   
Identification of pncA mutants involved in PZA resistance: M. tuberculosis PZase 
enzyme is encoded by the pncA gene (Scorpio and Zhang 1996). Mutation in the gene 
causing PZA resistant have been well characterized (Scorpio et al. 1997; Lemaitre et al. 
1999; Mestdagh et al. 1999; Cheng et al. 2000; Morlock et al. 2000; Huang et al. 2003; 
Portugal et al. 2004; Jureen et al. 2008) and are located along the whole gene as well as 
in the upstreamed putative regulatory region.  
Mutation in pncA may be responsible for the conformational change which may affect  
enzyme activity. While the mutation in putative regulatory region of the gene may 
hinders RNA polymerase to bind to the promoter, thus disturbing the active 
transcription. There are also reports regarding PZA resistant strains that maintain PZase 
activity (Cheng et al. 2000; Lee et al. 2001), this has lead to speculation of other 
mechanism than the PZase activity. However, partial inactivation of the pyrazinamidase 
may also lead wrong interpretation of the activity, an example of partial inactive PncA 
activity was encountered which is shown in  Fig. 49. PZase activity affects the rate of 
conversion of PZA to bactericidal POA, which would therefore be an important factor 
in determining the susceptibility of mycobacteria to PZA, this was also observed by Sun 
(Sun and Zhang 1999). Defective PZase activity caused by pncA mutations were also 
correlated with PZA resistance in M. tuberculosis (Scorpio and Zhang 1996; Scorpio et 
al. 1997; Sreevatsan et al. 1997; Zhang et al. 2008). 
PZA resistant strains must not always be PZase positive (Butler and Kilburn 1983) and 
thus do not necessarily always contains mutation in pncA gene. The same we have also 
encountered during the sequence analysis of the clinical strains of tuberculosis. This 
suggest for an alternative mechanism of the resistant organism to tackle with PZA. 
Pyrazinamidase however does have influence in the susceptibility as pzaA or pncA from 
M. smegmatis when introduced in to naturally PZA resistant M. tuberculosis BCG, the 
resistant M. tuberculosis BCG became susceptible to PZA (Guo et al. 2000). Similarly, 
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Sun (Sun and Zhang 1999) reported partial PZA susceptibility in M. bovis BCG when it 
was transformed with pncA gene from M. kansasii. M. kansasii  is also PZA resistant 
but having reduced PZase activity. On introducing pncA gene from M. avium, the 
organism became highly susceptible to PZA (Sun and Zhang 1999). Thus showing the 
direct relationship between PZase and PZA. 
 
Fig. 54. Multiple sequence alignment of nicotinamidases of P. horikoshii (PH999) (BAA30096), M. 
tuberculosis (PZase_Mtu) (AAB37768), M. smegmatis (AAD11442), E. coli (P, and, N-
carbamoylsarcosine amidohydrolase (CSHase) (P32400) of Arthrobacter sp, and YcaC (P21367) of E. 
coli (P21367). The residues conserved in the nicotinamidases are coloured in green. The residues 
conserved in all six sequences are coloured in red. The residues in the four loops that line the active site 
are underlined.(Du et al. 2001) 
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Fig. 55. Overview of mutations present in the pncA gene of M. tuberculosis. The residues conserved in 
the nicotinamidases are coloured in green. The residues conserved in all six sequences are coloured in 
red. The residues in the four loops that line the active site are underlined.(Du et al. 2001). Red: This 
study; Green: Studies from South Africa (Mphahlele et al. 2008); Blue: Studies from Sweden (Jureen et 
al. 2008); Black: Studies from Brazil (Rodrigues Vde et al. 2005); Green: Studies from Japan (Miyagi et 
al. 2004);  Studies from southeast Brazil (Barco et al. 2006);  Light Blue: TB from diverse geographic 
localities (Sreevatsan et al. 1997); Purple: Analysis of published literatures from different part of world 
(O'Sullivan et al. 2005). O : Point Mutation; I: Insertion, D :  Deletion.  
 
The mutations in pncA were  distributed equally over the whole gene (Fig. 36 and Fig. 
55) as in the previous studies (Scorpio et al. 1997; O'Sullivan et al. 2005; Rodrigues 
Vde et al. 2005; Barco et al. 2006; Jureen et al. 2008). The new mutations are being 
continuously reported in new studies. In a recently published paper (Mphahlele et al. 
2008) a new mutation common to our studies was published. There has been 197 
different mutations reported in the gene and its promoter region. It can thus be expected 
that more new mutation could be detected in the gene. The reason for the occurrence of 
wide variety of mutation in the gene is not known, it was only believed that the pncA 
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gene is located in a hotspot for mutation in the mycobacterial genome (Barco et al. 
2006).  
It is generally considered that mutations which lead to PZA resistance are distributed 
randomly along the gene, however some authors mentioned a certain degree of 
conservation of pncA mutations at  amino acid residues 3-17, 61-76 and 132-142 in 
PncA protein (Scorpio et al. 1997; Lemaitre et al. 1999; Park et al. 2001). The crystal 
structure of PZase of P. horikoshii shows that the resides 10 to 21, 128 to 133, and 52 to 
72 contribute most of the scaffold of the active site (Du et al. 2001). However revision 
of mutations in the gene (Fig. 55) shows that mutation in pncA gene are random and 
throughout the gene without showing any pattern. 
Another interesting feature found was duplicated nucleotide sequence in pncA gene in 
some strains. The  duplicated sequence could have been remnants of  a mobile element 
which was integrated between the repeats.  During the course of sequence analysis, it 
was observed that two types of different insertions ocurr which lead to tandem repeat of 
8 bp or 9 bp twice. In one of the sequence, where 9 bp (AGGTCGATG ) are added 
between 388-389 bp from the start codon, tandem repeat of AGGTCGATG  or 
GAGGTCGAT was observed (Fig. 37). Although Rodrigues (Rodrigues Vde et al. 
2005) also found the same insertion, they did not report it as repeat. Similarly, insertion 
of TCCTCGTC between 192-193 in pncA gene leads to two tandem repeat of 
TCCTCGTC ( 
Fig. 38). This was observed in three strains. This type of tandem repeat could be the 
remains of an IS element. Transposition of IS1660 inside the pncA gene was already 
described by Lemaitre (Lemaitre et al. 1999). With the known duplication only it was 
not possible to find the nature of the mobile element which was stationed previously.  
In addition, the results confirm that amid gene product of M. tuberculosis is unable to 
use PZA as substrate. Thus, as in M. bovis and M.bovis BCG, pncA is the only 
functional gene in M. tuberculosis coding for a functional PZAse. All strains of M.bovis 
reported till today are resistant to PZA due one single point mutation which completely 
inactivates the enzyme. 
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5 Summary 
1. Rifampicin is one of the most potent and most effective drug against 
tuberculosis. Rifampicin resistance in the M. tuberculosis strain is caused due to 
mutation in rpoB gene, which in turn effects the RNA polymerase (RNAP). The 
enzyme complex as a whole is a well known target for new drug development. A 
simplified technology for the RNAP assay for the screening of drug was devised 
in the work. The method established was cost effective, suitable for high-
throughput use, did not use radioisotopic material and utilized natural 
nucleotides. With the devised assay several drug candidates were tested. 
2. Attempt was done to reconstitute M. tuberculosis RNAP. The subunits of M. 
tuberculosis RNAP viz. RpoA, RpoB, RpoC and RpoZ were individually 
cloned, expressed and purified and attempt was done to constitute core enzyme. 
However functional reconstitution was not achieved during the work. 
3.  Pyrazinamide (PZA) is a nicotinamide analog which is used as a frontline drug 
to treat tuberculosis. The exact mechanism of action of pyrazinamide (PZA), one 
of the most important antimycobacterial drug is still elusive. Mutations in pncA 
gene of M. tuberculosis are mostly responsible for the resistance developed by 
M. tuberculosis against PZA. 
4. In other to further understand the molecular basis of PZA resistance in M. 
tuberculosis, DNA sequence of pncA from PZA resistant and susceptible clinical 
isolates of M. tuberculosis were analysed. The analysis identified 11 different as 
yet unreported mutations. 
5. Further the pncA gene of M. tuberculosis H37Rv was cloned in  E. coli BL21 
(DE3) and purified up to homogeneity. Direct cell free PZase assay from the 
purified enzyme was performed using PZA as a substrate on the basis that POA, 
an end product of PZA reacts with Mohr’s salt to produce orange-reddish 
product. A High throughput enzymatic Cell free PZase assay was developed in 
96 well plate, which can be further used for the exploration of novel therapy for 
TB. 
6. Thus, by the  method described in this study quantitative results for pncA 
(PZAse) of a mycobacterial strain  could be obtained within 2-3  days as 
compared to several weeks by currently standard methods.  
7. In addition, the results confirm that amidD gene product of M. tuberculosis is 
unable to use PZA as substrate. Thus, as in M. bovis and M.bovis BCG, pncA is 
the only functional gene in M. tuberculosis coding for a functional PZAse. All 
strains of M.bovis reported till today are resistant to PZA due one single point 
mutation which completely inactivates the enzyme. 
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7 Appendix 
7.1 Abbreviations 
 
ATP Adenosine triphosphate 
BCG Bacille Calmette-Guerin 
bp Base pair 
BSA Bovine Serum Albumin 
CTP Cytidine triphosphate 
Dept. Department 
DNA Desoxiribonucleic acid 
dNTP Desoxiribonucleoside triphosphate 
ds Double Stranded 
EDTA Ethylenediamine tetraacetic acid 
g Acceleration of gravity 
GTP Guanosine triphosphate 
h Hour 
His Histidine 
HIV Human immunodeficiency virus 
hsp60 Heat shock protein 60 
HTS high-throughput screening  
IPTG Isopropyl-thio-β-Dgalactopyranoside  
IS  Insertion Sequence 
KAN Kanamycin 
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kb Kilo base pair 
kDa Kilodalton 
kV Kilovolt 
LB Luria Bertani medium 
M Molar 
Mb Mega basepare 
MDR Multidrug resistant 
MIC Minimum Inhibiting Concentration 
min Minute 
mM Millimolar 
MW Molecular weight 
NAD Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide 
NADP Nicotinamide adenine dinucleotide phosphate 
NADPH nicotinamide adenine dinucleotide phosphate 
NCBI National Center for Biotechnology Information 
NTA Nitrilotriacetic acid 
NTP Nucleoside triphosphate 
OADC Oleic acid, albumin, dextrose, catalase  
OD Optical density 
PAGE polyacrylamide gel electrophoresis 
PBS Phsphate buffered saline 
PCR Polymerase chain reaction 
PEG Poly ethylene glycol 
POA Pyrazoic acid 
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PVDF Polyvinylidene fluoride  
PZA Pyrazinamide 
PZase Pyrazinamidase  
R Resistant 
RLU Relative light unit 
RNA Ribonucleic acid 
RNAP RNA polymerase 
rpm Rounds per minute 
RT Room temperature 
s Second 
S Susceptible 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
TAE Tris-Acetate-EDTA  
TB Tuberculosis 
TEMED N,N,N’,N’-tetramethylethylenediamine 
TTP thymidine triphosphate 
U Unit 
UTP Uridine triphosphate 
UV Ultraviolet light  
WHO World Health Organization 
XDR Extreme Drug Resistance 
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7.2 Maps of plasmids 
 
pLEXSR5-6
4510 bp
Kan
hsp65 Promotor
M.rep E.rep
Bgl  II (2797)
Eco R I (4371)
Hin d III (4377)
Kpn  I (3941)
Nco  I (4347)
Nde  I (4341)
Not  I (2018)
Not  I (3930)
Xho  I (150)
Xho  I (2423)  
 
 
pLEXSR6-6
4522 bp
Kan
hsp65 Promotor
E.repM.rep
Bgl  II (2797)
Eco R I (4383)
Hin d III (4389)
Kpn  I (3941)
Nco  I (4359)
Nde  I (4353)
Not  I (2018)
Not  I (3930)
Xho  I (150)
Xho  I (2423)  
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pLEXSR9-11
4570 bp
His Tag
Thrombin
Kanhsp65 Promotor
M.rep E.rep
Bgl  II (2797)
Eco R I (4431)
Hin d III (4437)
Kpn  I (3941)
Nco  I (4407)
Nde  I (4401)
Not  I (2018)
Not  I (3930)
Xho  I (150)
Xho  I (2423)  
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